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Chapter 1
General introduction
People in present days in Western Europe are achieving a higher age 
than ever and its population is getting older. Based on recent surveys, the 
prevalence of neurologic diseases within aging population is increasing 
[1]. One of them is Parkinson’s disease (PD), which affects mostly people 
in the age over ﬁ  fty. Worsening mobility, causing problems with activities 
of daily living, pain and communication problems due to rigidity of facial 
muscles, are the main reasons of their decreasing quality of life [2]. This 
study is focused on the role of psychological variables, which could be 
associated with quality of life in PD patients. After their identiﬁ  cation a 
discussion about opportunities of improvement patient’s quality of life 
can be opened. In the ﬁ  rst chapter a description of PD, the main aims of 
the thesis, theoretical models and research questions will be presented.         
1.1 Parkinson’s disease
In 1817 James Parkinson, a medical doctor, for the ﬁ  rst time described the 
disease as “involuntary tremulous motion, with lessened muscular power, in 
parts not in action and even when supported; with a propensity to bend the trunk 
forwards, and to pass from a walking to a running pace: the senses and intellects 
being uninjured“ [3].
Prevalence/Incidence
Parkinson’s disease is the second most common neurological disorder 
affecting disability after stroke [4,5]. The disease occurs more frequently 
in men than in women in every decade of life, which is explained by the 
neuroprotective effects of estrogens [6-8]. 
Prevalence and incidence of PD in European countries was 
estimated at approximately 108 to 257/100,000 and 11 to 19/100,000 per 
year, respectively, but it varied from country to country. The prevalence 
in Asia countries is slightly lower, all-age prevalence varied from 51.3 
to 176.9/100,000 persons and the incidence from 6.7 to 8.7 per 100 000 
persons per year [9]. Prevalence and incidence rates are the lowest in 
African countries – the crude prevalence varied from 7 to 31.4/100,000 
persons and the crude incidence rate of PD was 4.5/100,000 persons per 
year [10]. When only older age groups (≥ 60 years) were included, rates 
of prevalence and incidence in Europe varied from 1280 to 1500/100,000 8 CHAPTER  1
persons and 346/100,000 persons per year, respectively [11]. Baldareschi 
and colleagues estimated an average annual incidence rate of 346/100,000, but 
only persons aged 65–84 years were included in their study population [12]. 
Criteria for diagnosis
Parkinson’s disease (PD) is an age-related neurodegenerative disease, 
characterized by relatively selective nigrostriatal dopaminergic 
degeneration. First symptoms of PD appear, when the remaining 
production of dopamine has been fallen below 20% of its original 
production or when 50% of the cells of the substantia nigra have been 
destroyed [2]. The criteria for diagnosis are including physical and mental 
symptoms which have an impact on quality of life (QoL) of patients 
with PD [14,13]. There are four main clinical symptoms of the disease: 
tremor, rigidity, slowness and problems with walking and posture [2]. 
The important physical symptoms of PD are also a blank stare (the so-
called “Parkinson’s mask”) and troubles with manual dexterity [15]. Non-
motor symptoms of the disease may include depression, sleep disorders, 
hallucinations and delirium, some of which may be related to treatment 
by dopaminergic drugs [16-18]. Table 1.1 is showing the main motor and 
non-motor symptoms. 
Table 1.1 Motor and non-motor symptoms of Parkinson’s disease 
Motor Non-motor symptoms
Tremor
Mood disorders:
Depression, anxiety and apathy
Rigidity
Cognition:
Bradyphrenia, dementia
Bradykinesia
Sleep disorders:
Sleep fragmentation, REM sleep disorders, excessive daytime sleepiness, 
altered sleep–wake cycle
Postural instability
Autonomic disorders:
Hypotension, constipation, detrusor dyssynergia, sexual dysfunction, 
seborrhea, sweating
Treatment and healthcare services
Although, over past three decades cell-based therapies, based on 
replacement of the lost dopamine neurons by transplantation, are 
developing, PD is still considered as an illness that cannot be cured [2,19].  
There are several approaches to its treatment, from a “wait and see” policy 
to starting with drug treatment immediately after identifying the diagnosis, 
but so far neurologists did not reach consensus regarding treatment [20]. 
However, although curing PD is not yet possible, symptomatic treatment 
has improved in recent years. The most used symptomatic therapy for 9
PD is levodopa, introduced more than forty years ago, which efﬁ  cacy is 
evident mostly in the beginning of the treatment [18,21]. However, after 
long using the levodopa the levodopa-induced side effects could appear: 
dyskinesias, motor ﬂ   uctuations or neuropsychiatric disorders [18]. 
Another possibility, which has been used for treatment of PD symptoms 
since the 1970s, are the dopamine agonists which are associated with a 
lower incidence of dyskinesias, but they have less beneﬁ  t on the motor 
function than dopamine itself, and there are increasing concerns about 
their side-effect proﬁ  le [22]. Next possibilities are Catechol-O-Methyl-
Trasnsferase (COMT) inhibitors in conjunction with levodopa for longer-
lasting treatment and selective MAO-B inhibitors for adjunctive therapy 
and from 2006 also in monotherapy.  An algorithm suggests to start with 
dopamine agonists in younger patients and only later to combine it with 
other antiparkinsonian drugs. In patients over eighty it is recommended 
to start with levodopa. In Slovakia patients use antiparkinsonian therapy 
according international guidelines [23,24].  
  In the examined sample of PD patients, 12% used only L-dopa, 
and 24% used only dopamine agonists. L-dopa in combination with 
Catechol-O-Methyl-Trasnsferase (COMT) inhibitors was used by 25.3% of 
the patients, and L-dopa with dopamine agonists was used by 20% of the 
patients. The combination of L-dopa, a COMT inhibitor and dopamine 
agonists was used by 16% of the patients from our sample [25].
Rehabilitation and physical exercises are used for slowing down 
the secondary damaging of motor functions [2]. However, physical 
therapeutists and trainers should take into account neurophysiologic 
aspects of motor impairment in PD, e.g., akinesia, the inability to perform 
sequential movements, impairments in the pacing of rhythmic movements, 
and impairments in the predictability of movements [26]. A quite novel 
kind of treatment of motor functions in PD patients is the combination of 
motor imagery and real practice, which seems to be effective, especially 
for reducing bradykinesia [27].
Information about quality of life in patients with PD is important for 
a neurologist, as it can help him to make appropriate decisions. Hence, it 
is important to pay attention to study ﬁ  ndings in this group of patients 
and to continue exploring the variables which can indicate changes in 
their quality of life. To improve the overall health status of the patients 
and to maintain their independence and active life is one of the challenges 
in neurology. 
1.2 Impact of Parkinson’s disease on their quality of life
PD is not a fatal diagnosis by itself, but in people seriously disabled, 
suffering from the disease several years, it will inﬂ  uence their general 10 CHAPTER  1
physical and mental conditions as well as their social functioning, which 
could decrease the patient’s quality of life and also reduce the length of 
his/her life [4,28]. After 2–5 years from the onset of disease, up to 50% of 
PD patients develop motor complications which include regular visits of 
neurologist and intensive rehabilitation [29]. The progressive nature of 
PD and its increasing prevalence have resulted in a substantial economic 
burden to society, health care providers, individual patients and their 
families [29,30].
Physical domain
The poorer quality of life of PD patients is mainly associated with functional 
status and disease severity [25,31,32], a fact conﬁ  rmed by several studies. 
In a 4-year follow-up study, disease severity was signiﬁ  cantly the most 
important factor for a lower QoL [33]. Altered gait and postural instability 
also contributed to the worsened QoL of these patients [32,34].  
Psychological domain
There are several psychological aspects associated with PD decreasing 
QoL in patients. The presence of fatigue in PD patients predicts the 
worsening of all QoL domains measured by the Parkinson’s Disease 
Questionnaire-long form (PDQ-39), a disease speciﬁ  c measurement; that 
is, primarily bodily discomfort, mobility and emotional well-being [35]. 
Depression is the major contributor to the explanation of the variance in 
QoL scores [2,36-38]. The rate of depression in community-based samples 
of patients with PD is approximately 30–40%, ranging from 20 to 70%, 
but only a minority of these patients (approximately 2.7 to 7.7%) fulﬁ  lls 
the criteria of DSM IV for depression [39]. Physical impairment due to 
disease, such as increased disease severity, recent disease deterioration 
and the occurrence of falls, is a condition for higher levels of depression in 
PD patients. It was also found that depression is more strongly associated 
with patients’ perception of being handicapped than by actual disability 
and can reﬂ  ect a pessimistic outlook on the future [36,37]. Worse overall 
mental condition and patients’ memory complaints are also signiﬁ  cant 
factors associated with lower QoL [2,32,37]. Personality traits, such 
as extroversion, neuroticism or Type D personality, were till now not 
examined in the context of Parkinson’s disease.
Social domain
The social aspect of PD most negatively inﬂ  uencing the social domain of 
QoL of patients is isolation, which is due to the embarrassment caused 
by the symptoms and problems with communication [40]. Patients 
mentioned that major social problems associated with the disease were the 
loss of social contact, behavioral problems, family members under strain 
and communication problems within the family [41].11
1.3 Measuring quality of life in patients with Parkinson’s disease
For measuring QoL in patients with PD, disease speciﬁ  c instruments and 
generic instruments can be used. The use of this variety of instruments is 
resulting into difﬁ  culties in comparing QoL of PD patients from different 
studies on the one hand and with other groups of chronically ill patients 
on the other hand. 
Disease speciﬁ  c measurements
Disease-speciﬁ   c instruments widely used are the Parkinson’s Disease 
Questionnaire (PDQ-39) designed by Peto et al. (1995) and the Parkinson’s 
Disease Quality of Life questionnaire (PDQL) developed by De Boer et 
al. (1996) [42,43]. In several studies also the Parkinson’s Impact Scale 
(PIMS) was used, useful in identifying potential problems areas, and the 
Parkinson LebensQualität (Parkinson QoL questionnaire) (PLQ) used 
mostly in German studies [44]. 
 
Generic measurements 
There are also generic (disease non-speciﬁ  c) instruments used to compare 
PD patients to the general population, or to other disease groups. 
Predominantly the Medical Outcome Study Short Form (SF-36) and the 
EuroQoL 5D (EQ-5D) are used, mostly successfully used in many studies 
where different groups of patients were compared.
1.4 Conceptual framework
QoL is a complex and multidimensional construct that has been deﬁ  ned as 
“a concept encompassing a broad range of physical and psychological characteristics 
and limitations which describe an individual’s ability to function and to derive 
satisfaction from doing so” [45]. It includes the following domains: the 
physical, encompassing the ability to conduct activities of daily living; 
the psychological or emotional; and the social, encompassing interactions 
with family, friends, and community [46].
Various factors are inﬂ   uencing QoL in chronically ill patients. 
Clinical and socio-demographical factors, which are most frequently 
examined, are not the only factors predicting QoL. In practice, individual 
differences between patients were observed – patients with the same 
level of symptoms (objectively with the same score in neurological scales) 
informed the neurologist about different satisfaction with their lives. 
There were several models in previous decades, which tried to 
explain the disablement process. Saad Nagi, a sociologist from Egyptian 
origin, started in the sixties of the twentieth century with this type of 
modeling, by introducing a dynamic view on disablement [47-49]. His 12 CHAPTER  1
model describes the disablement process through concepts as are shown 
in Figure 1.1. Main terms are: 
- active pathology – a state of the body’s defences and coping 
mechanisms caused by infections, traumas or other pathologies
- impairment – a loss of or abnormality of the tissue, organ and body 
system level
- functional limitations - limitations in an individual’s ability to 
perform the tasks and obligations of his ususal roles and daily 
activities
- disablement - limitations in performing socially deﬁ  ned roles, e.g. 
employment or self-care
Figure 1.1 Nagi’s model of disablement and functional consequences of a pathological process in the body [48] 
In 1976 the WHO published an upgraded model which analyzed, described 
and classiﬁ  ed the consequences of disease and which distinguish between 
impairment, disability and handicap. It was named International 
Classiﬁ  cation of Impairments, Disabilities and Handicaps (ICIDH) [50]. 
It sees impairment, disability and handicap as three different levels of 
pathology consequences of pathological processes, which are related to 
different levels of experience and individual awareness [49].
The conceptual framework of this study follows the ICF model – the 
International Classiﬁ  cation of Functioning, Disability and Health (ICF). 
The ICF is the WHO’s model for measuring health and disability at both 
individual and population levels. This widely used model was translated 
into several languages and it was used in studies from 191 countries and 
deﬁ  nes disablement as the result of the interaction among the domains of 
body, individual, and environment [51]. 
The ICF model is composed from 2 parts, each with 2 components 
(see Figure 1.2):
- part I: – Functioning and Disability
a) Body functions and Structures – physiological and anatomical 
changes
b) Activities and Participations – the capacity to executing tasks in a 
standard environment and the performance to executing tasks in the 
current environment
Active pathology  Impairment  Functional 
limitations 
Disablement
Cellular  Body system
Dimensions of 
the Model 
Whole person  Person’s relation 
to society 
Level of 
Disablement 13
- part II: – Contextual factors 
a) Environmental Factors – external inﬂ  uences on functioning and 
disability 
b) Personal Factors – internal inﬂ   uences on functioning and 
disability 
Figure 1.2 The WHO model of the International Classification of Functioning, Disability and Health [51]
The ICF could be applied in a wide range of scientiﬁ  c and also practical 
areas, e.g. social security, management of health care, prevention and 
health promotion on a national, but also on an international level [51]. 
1.5 Aims of the study and research questions
The main aim of this cross-sectional study was to explore psychological 
factors (which are included in the personal factors of the ICF model) 
associated with quality of life – neuroticism, extroversion, negative 
affectivity, social inhibition, Type D personality and mood disorders 
(anxiety, depression). Associations explored in the study were derived 
from the theoretical background from theories dealing with the concept 
of QoL (Figure 1.3).   
Activity
limitations 
Health Condition
disorder or disease 
Environmental 
Factors 
barriers  
Personal Factors 
internal influences 
Participation
restriction 
Body Function 
and Structure 
impairment 14 CHAPTER  1
Figure 1.3 Design of the variables used in the thesis
The main objectives of the thesis therefore include:
1)  to explore whether psychological factors were associated with the 
perception of quality of life in patients with Parkinson’s disease;
2) to investigate whether psychological factors of patient’s help-
seeking behavior may be associated with quality of life of patients 
with Parkinson’s disease.
The objectives led to the following general research questions (RQ):
1) to explore the associations between various personality traits, 
neuroticism, extroversion, negative affectivity, social inhibition 
and Type D personality and quality of life in Parkinson’s disease 
patients. In addition, gender differences were examined as well 
(Chapter 2 and Chapter 3);
2)  to explore differences between delayers and non-delayers 
regarding psychological factors associated with quality of life 
in patients with Parkinson’s disease and the impact of fear and 
anxiety on help-seeking behavior in non-parkinsonian diseases 
(Chapter 4 and Chapter 5);
3)  to compare the role of the association of psychological factors – 
Type D personality, anxiety and depression – with quality of life 
in patients with Parkinson’s disease and multiple sclerosis (MS) 
(Chapter 6).
1.6 Structure of the thesis and summary of contents
In Chapter 1 a General Introduction on Parkinson’s disease and the patient’s 
quality of life was presented. 
In Chapter 2 the associations between extraversion, neuroticism and 
quality of life were presented. In this chapter personality traits for women 
and for men will be analyzed separately. 
QoL 
Mood disorder 
Personality traits
(gender differences) 
Patient’s delay 
Disease severity 
 15
Chapter 3 is focused on Type D personality, negative affectivity 
and social inhibition as predictors of perceived quality of life. Gender 
differences in models for men and women will be presented as well.
Patient’s delay is associated with decreasing of quality of life in 
many diagnoses. In Chapter 4 a systematic review was performed for to 
explore, how fear, and its intensity, was associated with patient’s delay in 
chronic and also acute disease.
Personality traits could inﬂ  uence decision making in help seeking, 
as well. In Chapter 5 differences in personality traits between delayers and 
non-delayers in patients with PD were explored. 
In Chapter 6 we are comparing patients with Parkinson’s disease with 
patients with multiple sclerosis regarding personality and depression and 
anxiety. 
In Chapter 7 we summarized the results of this study and discussed 
them. Furthermore we are trying to outline practical implication of the 
results of the research in neurological practice. Results of our research 
lead to the suggestions for further research of the quality of life in patients 
with Parkinson’s disease.
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Abstract 
Purpose: Personality traits appear as determinants of quality of life (QoL) 
in most chronic diseases. The aim of this study is to explore whether 
neuroticism and extraversion contribute to the variance in QoL in patients 
with Parkinson’s disease (PD) when controlled for age, functional status 
and disease duration. 
Methods: The Parkinson’s Disease Quality of Life Questionnaire (PDQ-
39) was used to assess QoL and the Uniﬁ  ed Parkinson’s Disease Rating 
Scale (UPDRS) for disease severity. Neuroticism and extraversion were 
measured with the Eysenck Personality Questionnaire (EPQR-A). Multiple 
linear regression analysis was then used to assess the contribution of 
neuroticism and extraversion to QoL. 
Results: The sample consisted of 153 PD patients (48.4% women; 67.9±9.3 
years; mean disease duration 7.5±5.8 years). Neuroticism was, after 
disease severity, the second most important variable associated with QoL 
in PD patients, in particular for domains associated with psychological 
processes:  emotional well-being,  social support,  stigma and communication. 
A higher score in extraversion was signiﬁ  cantly associated with better 
emotional well-being in males, but surprisingly, with worse emotional well-
being in females. 
Conclusions:  After functional status, personality traits were clearly 
associated with QoL in PD patients. Therefore, they should be taken 
into account by healthcare professionals in their appraisal of patient 
complaints.
Introduction 
Parkinson’s disease (PD) is a progressive neurodegenerative disease 
that affects 1% of all people over 60 years of age and around 2% of the 
population over 80 years of age. It includes both physical and mental 
symptoms which have an impact on the quality of life (QoL) of those with 
the disease [1,2]. The physical symptoms of PD typically affecting QoL are 
tremor, rigidity, slowness, a blank stare (the so-called “Parkinson’s mask”) 
and troubles with manual dexterity [3]. Mental symptoms may include 
depression, sleep disorders, hallucinations and delirium, some of which 
may be related to therapy using dopaminergic drugs [4,5]. The social 
components of PD involve isolation due to the embarrassment caused by 
the symptoms and problems with communication [6]. 
With regard to basic sociodemographic and clinical variables, 
increasing age and higher disease duration have been found to be 
associated with decreased QoL in PD patients [7]. In addition, mildly 
signiﬁ  cant differences in disability and QoL have been noted between the 23
genders in general: women have reported greater disability and reduction 
of QoL than men [8]. Gender differences are also present in the incidence 
of PD: the disease occurs more frequently in men than in women in every 
decade of life [9]. One of the various theories explaining these differences is 
that they may result from the neuroprotective effects of estrogen [8,10,11]. 
Some personality traits, such as neuroticism and extraversion, are 
assumed to be factors that contribute to the perception of health status 
and thus lead to a worse perception of QoL by people with several chronic 
diseases [12-14]. People who score high on the neuroticism scale manifest 
more worries, uncertainties and anxiety [15]. Because these people are 
more likely to behave overly emotionally and react too strongly to all sorts 
of stimuli, their neuroticism seems to be associated with psychological 
dysfunction [15,16]. Some authors have reported that neuroticism also 
appears to be associated with the tendency to recall physical symptoms as 
being worse than they really were [17,18], thus indirectly contributing to a 
lower perceived QoL [19]. Quality of life of patients with chronic diseases 
may also be inﬂ  uenced indirectly by extraversion. Extravertly oriented 
people have a tendency to be sociable and to prefer changes, and there is 
a high probability that they will crave excitement and act impulsively [15]. 
It has been observed that people with a low score in extraversion are more 
self-centered and are more sensitive to stress than extraverted people [20]. 
Therefore, it might be hypothesized that extraversion inﬂ  uences the level 
of coping with chronic disease and can thus also inﬂ  uence the level of 
QoL [20,21]. 
    The QoL of patients with PD is frequently studied, but very little is 
known about the associations between personality traits and QoL in these 
patients. The aim of this study, therefore, is to explore whether personality 
traits (neuroticism and extraversion) contribute to the variance in QoL in 
patients with PD when controlled for disease severity, disease duration 
and age. In addition, this study analyzes whether gender differences in 
the QoL of PD patients can be attributed to gender-related differences in 
extraversion and neuroticism in these patients. 
Methods
Subjects and procedure 
Data collection took place between February 2004 and February 2006. One 
hospital in Bratislava as well as 4 hospitals and 17 outpatient neurology 
clinics in the eastern part of the Slovak Republic cooperated in this study.
Questionnaires were sent to patients diagnosed with Parkinson’s 
disease three weeks before the interview. All patients were diagnosed 
according to the United Kingdom Parkinson’s Disease Society Brain 
Clinical Criteria [22]. Exclusion criteria were deﬁ   ned as follows: a) 24 CHAPTER  2
patients older than 85 years, because of the high probability of other co-
morbidities and movement disabilities of a non-parkinsonian character 
and b) an MMSE score lower than 23 points.  
An interview with each patient took place three weeks after the 
invitation. After each interview, a neurologist assessed the severity of 
the patient’s disease using the Uniﬁ  ed Parkinson’s Disease Rating Scale 
(UPDRS Version 3.0) [23]. The patients’ mental status was assessed with 
the Mini-Mental State Examination (MMSE) [24]. The structured interview 
consisted of questions about the patient’s medical history and subjective 
feelings that were not part of the questionnaire. Sociodemographic data 
were derived from medical records and from questionnaires ﬁ  lled in by 
the patients themselves. 
The study was conducted after informed consent was obtained from 
the patients prior to the study. The local Ethics Committee of the University 
Hospital in Kosice approved the study in Kosice on 17 December 2002.
Measures
Disease severity 
The Uniﬁ   ed Parkinson’s Disease Rating Scale (UPDRS) is currently 
used as a standard reference scale in clinical practice and in research for 
assessing disease severity in patients with PD. Ratings are observation-
based, and scores are obtained by interview and physical examination. 
The scale consists of four parts: mentation and mood (part 1), activities of 
daily living (part 2), motor function (part 3) and complications resulting 
from dopaminergic therapy, including motor ﬂ  uctuations and dyskinesias 
(part 4). Parts 1, 2 and 4 are interview-based, while part 3 is based on a 
clinical examination by a health professional and represents the patient’s 
condition at the time of the examination. Patients can score from 0 to 176, 
with higher scores indicating increased disease severity [23].
Extraversion and neuroticism 
The Eysenck Personality Questionnaire Revised Abbreviated (EPQR-A) was 
used for measuring Extraversion and Neuroticism [25]. The questionnaire 
was validated in the Czech Republic in a sample of 3565 people [26]. The 
Slovak and Czech languages are similar, and today’s Czech and Slovak 
Republics were, prior to 1993, united in a single country. Thus, results 
from Czech Republic could be valid also for the needs of this research. The 
questionnaire consists of 24 items divided into 4 subscales: extraversion, 
neuroticism, psychoticism and the lie scale. Items are scored on a Yes (=1) 
No (=0) basis, and the overall score for each subscale ranges from between 
0–6, with higher scores indicating higher levels for the personality traits. 25
Internal reliability found across the samples was .74-.84 for the extraversion 
subscale and .70-.77 for neuroticism [27]. In the present study Cronbach’s 
alpha was .85 for extraversion and .72 for neuroticism.
Quality of life 
The Parkinson’s Disease Questionnaire - long form (PDQ-39) is a disease-
speciﬁ  c instrument developed for measuring health-related quality of 
life in patients with Parkinson’s disease. Its 39 items are divided into 8 
scales: mobility (10 items), activities of daily living (6 items), emotional well-
being (6 items), stigma (4 items), social support (3 items), cognition (4 items), 
communication (3 items) and bodily discomfort (3 items). In response to 
each question, respondents select from answers ranging from never (0), 
occasionally (1), sometimes (2), often (3) and always (4). Each scale and the 
summary index were transformed in order to have a range from 0 (=no 
problem at all) to 100 (=maximum level of a problem) [28]. We translated 
the questionnaire from its original source [28] into the Slovak language and 
then translated it back into English using another translator. Two Slovak 
native speakers with mastery of the English language ﬁ  rst translated the 
questionnaires from English into Slovak. The questionnaires were then 
re-translated from Slovak back into English, this time by a native English 
speaker with mastery of the Slovak language. The discrepancies between 
the different versions of the questionnaires were then discussed. We 
checked the basic psychometric characteristics of the scale, but these have 
not yet been published. In the present study, the Cronbach’s alphas were 
as follows: .93 (mobility), .91 (activities of daily living), .85 (emotional well-
being), .88 (stigma), .75 (social support), .67 (cognition), .76 (communication) 
and .80 (bodily discomfort).
Statistical analysis 
The Statistical Package for the Social Sciences (SPSS 14.0.1.) software 
was used to analyze the data. Firstly, independent sample t-tests were 
conducted to assess differences between the genders in disease severity, 
age, disease duration, extraversion and neuroticism. As a second step, a 
difference of proportions test (CIA) was used to assess gender differences in 
partnership and education [29]. Thirdly, Pearson’s correlation coefﬁ  cients 
were used to determine the strengths of the relationships between the 
study variables. Finally, multiple linear regression analyses were used to 
assess the contribution of the independent variables age, gender, disease 
duration, functional status (UPDRS) and personality traits (E and N) and 
to explain the variance of the dependent variables - the dimensions of the 
PDQ-39. Identical multiple linear regression analysis was performed for 
males and females separately. 26 CHAPTER  2
Results
Out of 512 patients with Parkinson’s disease, 160 agreed to participate and 
ﬁ  lled in the questionnaires. Forty-one of the 512 refused to participate, 
and 311 did not respond to the invitation. Seven patients were excluded 
after the personal interview because of the exclusion criteria. The ﬁ  nal 
sample consisted of 153 patients (response rate 31.3%). Non-respondents 
differed signiﬁ  cantly from the analyzed group in age (mean difference 
1.69 yrs., SE=.87; t=-1.95; 95% CI .010 – -3.39), and there were signiﬁ  cantly 
more women than men among the non-respondents (difference -0.0110; 
SE=.041; 95% CI -.091 – .069).
Descriptive statistics
Females made up 48.6% of the participants and males 51.4%, with a mean 
age of 67.9±9.3 years (range 44-83). The mean disease duration was 7.5 ± 5.8 
years (range 0-34). One hundred and four patients from the sample (68%) 
lived with a partner, and 49 patients (32%) were widowed, divorced or 
single. Fifty-two patients (34%) had completed elementary education, 84 
patients (55%) secondary education and 17 patients (11%) had a university 
education. Disease severity in the patients varied from 5 points to 97, with 
a mean score (38.8) on the UPDRS representing medium disease severity. 
All patients used antiparkinsonian therapy according to international 
guidelines [30,31]. 
Gender differences in the study variables 
Males and females did not differ in age, disease duration and disease 
severity. No differences between genders were found with regard to the 
psychological variables extraversion and neuroticism. There were no 
differences between genders in the scores of the overall QoL and in PDQ-
39 dimensions, except for bodily discomfort (P=.05), where women scored 
signiﬁ  cantly higher (Table 2.1).
Results of correlation analyses
Table 2.2 presents the correlations between the PDQ-39 and age, disease 
duration, disease severity, extraversion and neuroticism for males and 
females separately. Disease severity signiﬁ  cantly correlated with all scales 
of the PDQ-39, except for satisfaction with social support in men. In women 
it played a less important role. 
Examining the relationships between variables by means of Pearson’s 
coefﬁ  cients showed signiﬁ  cant correlations between extraversion on one 
hand and mobility and activities of daily living on the other. Females with 
higher scores for extraversion reported better QoL in the dimension of 
activities of daily living, in contrast to males, for whom extraversion did not 27
appear to be important for any of the study variables.
The correlations show a strong relationship between nearly every 
sub-scale of PDQ-39 and neuroticism. For females, neuroticism is the 
main variable correlating with the QoL scales.
Overall QoL, represented by the PDQ-39 summary index, correlated 
with disease severity in both genders. In females it also correlated with 
neuroticism, and in males with disease duration.
Table 2.1 Characteristics of the sample – percentages, means and standard deviations (SD) of study 
variables.   
Males Females Total sample t-tests/CIA
Number of subjects (%) 79 (51.6) 74 (48.4) 153 (100)
Mean age in years (SD) 68.5 (9.2) 67.3 (9.3) 67.9 (9.3) ns
Mean disease duration in years (SD) 7.7 (5.7) 7.4 (5.8) 7.5 (5.8) ns
Disease severity – UPDRS (SD) 38.8 (22.2) 34.9 (18.7) 36.9 (20.6) ns
Married or living with a partner (%) 66 (83.5) 38 (51.4) 104 (68)
Education elementary  (%)
   secondary (%)
 university  (%)
22 (27.8) 30 (40.5) 52 (34)
44 (55.7) 40 (54.1) 84 (55)
13 (16.5) 4 (5.4) 17 (11)
Quality of Life – PDQ-39 total (SD) 56.9 (17.4) 61.2  (16.4) 58.9 (17.0) ns
   Mobility (SD) 60.2 (25.0) 66.4 (23.4) 63.2 (24.4) ns
   Activities of daily living (SD) 58.2 (26.0) 57.5 (27.3) 57.9 (26.6) ns
   Emotional well-being (SD) 59.9 (20.6) 65.5 (19.8) 62.6 (20.4) ns
   Stigma (SD) 53.7 (25.0) 54.5 (27.3) 54.1 (26.0) ns
   Social support (SD) 38.8 (18.0) 42.2 (20.7) 40.4 (19.4) ns
   Cognition (SD) 57.2 (20.1) 60.6 (18.6) 58.9 (19.4) ns
   Communication (SD) 49.9 (21.4) 48.9 (20.3) 49.4 (22.6) ns
   Bodily discomfort (SD) 69.7 (23.5) 80.9 (20.2) 75.2 (22.6) t≤.05
Extraversion (SD) 2.7 (2.2) 2.7 (2.3) 2.7 (2.2) ns
Neuroticism (SD) 2.1 (1.8) 2.7 (1.9) 2.4 (1.9) ns
Abbreviations: SD – standard deviation, ns – non-significant
 
Model of predictors of QoL 
Multiple linear regression analyses were performed in order to identify 
how much the variance of the dependent variables (mobility, activities of 
daily living, emotional well-being, stigma, social support, cognition, communication 
and  bodily discomfort) could be explained by the personality traits if 
controlled for the relevant sociodemographic and clinical variables (Table 
2.3). Table 2.3 (and also Table 2.4) shows the beta values, which reveal the 
relationships between the dimension and each value in the model. 28 CHAPTER  2
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The standardized Beta values were all measured in standard deviation 
units and so are directly comparable; e.g. a Beta of 0.78 means that increases 
of 1 point on the UPDRS total score is associated with an increase of .78 
point on the ADL scale.
The analyses were controlled for both disease variables (disease 
severity and disease duration) and for age. Higher age predicted worse 
scores in the subscales cognition and communication. Disease duration 
explained some of the variance, but only in communication. As expected, 
disease severity was the strongest predictor in almost all dimensions of 
PDQ-39, particularly in activities of daily living, mobility, emotional well-being, 
cognition, communication, and bodily discomfort, but it did not appear to be 
associated with the dimensions of social support and stigmatization. 
The model for overall QoL was fully covered only by disease severity 
and neuroticism. Extraversion appeared to be a signiﬁ  cant factor only for 
the dimension communication. Neuroticism was important mostly in the 
domains which are associated with some kind of psychological processes: 
emotional well-being, stigma,  social support and communication. However, 
neuroticism also explained some of the variance in activities of daily living 
and bodily discomfort. 
Gender differences in predictors of QoL
Table 2.4 presents the results of multiple linear regression analyses for 
men and women separately. Signiﬁ  cant gender differences were found in 
the predictors of the PDQ-39 sub-scales and for its summary index.
Out of all sociodemographic variables only age appeared to contribute 
signiﬁ  cantly to the total explained variance. Lower age was signiﬁ  cantly 
associated with stigmatization by illness and social support in women. Higher 
age was closely connected with lower scores in the domains cognition and 
communication in men. Disease duration had an impact on QoL only in 
the cognition subscale in men. Functional status was the only factor of 
the domains mobility,  activities of daily living and  emotional well-being in 
both genders. In males it also had an impact on communication and bodily 
discomfort, whereas in females it was connected with worse cognition.
Overall QoL was associated in both genders with disease severity 
and neuroticism. In men, 3.3% of the variance was also explained by 
extraversion. Extraversion explained 4.7% variance in communication in 
men and 6.4% in women. For both genders extraversion was an important 
part of the model of emotional well-being, though the observed relations 
were in the opposite direction. In women a high score for extraversion was 
associated with lower QoL in emotional well-being, whereas in men a higher 
score in extraversion was associated with a better score in this dimension. 
Neuroticism played an important role in emotional well-being and social 
support in both genders. In women neuroticism was also associated with 
stigmatization by illness and bodily discomfort. 32 CHAPTER  2
Discussion 
The aim of this study was to explore the contribution of personality 
traits (neuroticism and extraversion) to QoL in patients with PD and the 
contribution of possible gender differences in extraversion and neuroticism 
to QoL.
Disability, as expected, was the fundamental variable for QoL. In the 
intercorrelations between the variables, associations were found between 
disease duration and all PDQ-39 scales in men, but none in women. 
However, disease duration did not signiﬁ  cantly contribute to the models 
for each scale, except cognition in men. In addition to disease severity, the 
second most important factor for QoL in PD patients was neuroticism. 
Patients with higher scores on the neuroticism scale reported signiﬁ  cantly 
worse status in the domains of emotional well-being, stigma, social support 
and bodily discomfort. However, in separate models for males and females, 
neuroticism remained important only in the subscale of emotional well-
being in both genders. Neuroticism played a role in the subscales of stigma 
and social support in women, but it did not appear to be important in men 
due to the low validity of the social support model for men. 
Our results for neuroticism correspond with studies focusing on 
other patient groups, including patients with cognitive impairments, 
chronic pain and depression. A high level of neuroticism predicts the 
use of ineffective passive coping strategies, and those patients reported 
worse perception of their health problems [32-34]. It seems that due to 
societal inﬂ  uences, males and females develop different ways of coping 
and experiencing the world [34]. This phenomenon was also found by 
researchers who observed that a different score in neuroticism reﬂ  ects 
socially learned behaviour rather than biological differences. Gender-
role rather than gender had greater explanatory power with regard to 
neuroticism [35]. 
Extraversion was associated only with the subscale of communication: 
patients scoring higher on the extraversion scale seem to have fewer 
problems with communication skills. This corresponds with the study by 
Eysenck (1991) [15], where to be talkative is one of the characteristics of 
an extravertly-oriented person. However, there were differences between 
males and females in the model of emotional well-being. For both genders, 
extraversion is an important variable, but in the opposite direction. 
Extraverted males perceived their emotional well-being as better, but a 
higher score in extraversion was associated with worse emotional well-being 
in females. An explanation might be the associations between extraversion 
and coping strategies which have been found in several studies [20,21]. 
These differences could be explained by the supposed use of different 
coping strategies by males and females [36]. Our results support the 33
ﬁ   ndings of one Spanish study, which conﬁ   rmed a close association 
between extraversion and active coping strategies, which are used mostly 
by males [20]. 
Analysis presented in this paper explains only part of the variance 
in the QoL of patients with PD. The construct of QoL of those patients 
appears to be too complicated to be explained by psychological variables 
such as personality traits. Models of stigma, social support, cognition and 
bodily discomfort were signiﬁ  cant in general, but the adjusted R2 explains 
only a relatively small part of the variance. However, the relationships 
between study variables and these dimensions are signiﬁ  cant. Differences 
in the signiﬁ  cance between models for men and women suggest possible 
differences in the model variables. It can be hypothesized that models 
of QoL for men and women, especially in the dimensions stigma, social 
support,  cognition and bodily discomfort, are composed from different 
variables. The gender aspect of QoL appears to be an important focus for 
further studies.
A limitation of this study was the relatively low response rate, which 
may have an impact on generalizations of the results to the total population 
of PD patients. Non-respondents were older than respondents, so one 
might hypothesize that they refused to participate in the study because of 
serious motor complications in the advanced stages of PD and because of 
an increased need for help from their social surroundings. Regrettably, we 
have no information about the disease duration and the disease severity 
of the non-respondents.
Future research should concentrate on explaining how PD patients 
cope with health problems. The impact of personality traits on QoL is 
known from different studies on several chronic diseases. For example, 
close associations between extraversion, neuroticism and mental condition 
of the patients were conﬁ  rmed in hemodialysis patients [21]. However, in 
the ﬁ  eld of PD this is a relatively new idea.
Currently, the management of patients with PD is primarily aimed 
at prolonging life expectancy and diminishing motor disabilities [37]. The 
results of this study show that psychological traits are clearly associated 
with QoL as well and therefore should be taken into account by healthcare 
professionals in their appraisal of patient complaints. PD patients with 
high scores in neuroticism, especially females, may be considered as a 
population at risk for lower QoL. 
Effective management of PD patients should include a speciﬁ  c 
approach to improve QoL in the course of treatment. Our results are 
important for neurologists; they could use them in the phase of diagnosis 
where patients with higher scores in neuroticism could aggravate their 
symptoms, and also in the phase of the treatment where patients could 
differ in their perception of the efﬁ  cacy of the treatment. 34 CHAPTER  2
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Abstract
Objectives: Personality traits appear as determinants of quality of life 
(QoL) in most chronic diseases. Type D personality is characterized by 
ineffective coping strategies that reduce QoL in patients with coronary 
heart disease. The aim of this study was to evaluate whether Type D 
personality also predicts QoL in patients with Parkinson’s disease (PD). 
In addition, gender differences in Type D personalities are explored. 
Methods: The sample consisted of 153 PD patients (51.4% males; mean age 
67.9±9.3 years). DS-14 was used to measure Type D personality, negative 
affectivity (NA) and social inhibition (SI). The Parkinson’s Disease Quality 
of Life Questionnaire (PDQ-39) was used to assess QoL, and the Uniﬁ  ed 
Parkinson’s Disease Rating Scale (UPDRS) was used to assess functional 
status. The regression model consisted of disease severity, disease 
duration, age and DS-14 and its two scales (NA and SI). 
Results: Type D is negatively associated with overall QoL in PD patients 
and most subscales of the PDQ-39. Type D explained emotional well-being 
in both genders but was signiﬁ  cant in the models for stigma, cognition and 
communication only in men. NA and SI played a less important role in 
women in comparison with men.
Conclusion: Type D personality is an important part of the QoL model 
in PD patients of both genders, especially in the NA scale. The gender 
differences suggest that male and female PD patients require different 
coping strategies. 
Introduction
Parkinson’s disease (PD) obviously has a serious impact on a patient’s 
quality of life (QoL), predominantly in the physical and social domains 
[1,2]. Symptoms of PD that are likely to affect physical functioning are 
tremor, rigidity, slowness, gait disorders, freezing, falling, troubles 
with manual ability, constipation, dysphagia, fatigue, painful spasms 
and dyskinesias [3]. Problems affecting the mental functioning of PD 
patients include depression, sleep disorders, cognitive problems and 
sometimes hallucinations and delirium, which are related to therapy 
with dopaminergic drugs [4,5]. PD also interferes with social functioning, 
since PD patients have a higher risk of communication problems, are 
likely to become unemployed and often avoid social contact, as they may 
feel embarrassment due to their symptoms becoming manifest [6]. The 
diversity of symptoms associated with PD and its management leads to 
worse physical, mental and social well-being in comparison with people 
of the same age without symptoms of Parkinsonism [7]. 39
With regard to basic sociodemographic and clinical variables, 
increasing age and longer disease duration were found to be associated 
with decreased QoL in PD patients [8]. In addition, mildly signiﬁ  cant 
differences in disability and QoL were noted between the genders in 
general: women reported greater disability and reduction of QoL than 
did men [9]. 
Disease severity, especially in the context of motor function 
impairment of PD patients, signiﬁ   cantly reduces QoL and increases 
difﬁ  culties in activities of daily living [10,11]. However, some personality 
traits were assumed to contribute to the perception of health status and 
thus led to a worse perception of QoL in people with several chronic 
diseases as well [12,13]. The psychological variables frequently used in 
clinical studies are extroversion, neuroticism, anxiety and depression. 
It has been shown that these variables are assumed to be important 
contributing factors to QoL and perceived health status in healthy people 
as well as in people with a disease [14,15]. Differences between genders 
were also found in these variables, for example, in neuroticism: women 
consistently scored signiﬁ  cantly higher in neuroticism than men [16,17].
The construct of the Type D personality is related to poor cardiac 
prognosis in patients with coronary heart disease. The interaction between 
NA (which is closely related to neuroticism) and SI is associated with an 
increased risk of depressive symptoms, a higher number of reinfarctions 
and higher mortality rates [18]. About 10-20% of subjects from the normal 
population can be classiﬁ  ed as Type D, and this number increases to 30% 
in patients with coronary disease and to more than 50% in patients with 
hypertension [19,20]. Type D has also been characterized by ineffective 
coping strategies that reduce the QoL of patients with this type of 
personality [21]. 
Type D personality may be associated with health-related quality 
of life not only in cardiovascular diseases, but also in patients with other 
diseases [19]. The aim of this study was to evaluate whether the Type D 
personality, after controlling for disease severity, disease duration and 
age, explains QoL in patients with PD. In addition, gender differences in 
Type D are explored. The ﬁ  nal aim of this study was to evaluate whether 
there are gender differences in the association of NA and SI personality 
traits and QoL in patients with PD.
Methods
Subjects and procedure
Data collection took place between February 2004 and February 2006. 
One hospital in Bratislava and 4 hospitals and 17 outpatient neurologists/
clinics in the eastern part of the Slovak Republic gave us access to their 40 CHAPTER  3
databases of patients with Parkinson’s disease. Neurologists from these 
institutions, using the United Kingdom Parkinson’s Disease Society Brain 
Clinical Criteria [22], had previously diagnosed all patients included in 
the sample as suffering from Parkinson’s Disease.
Questionnaires were sent to these PD patients three weeks before an 
interview with the researchers. Exclusion criteria were deﬁ  ned as follows: 
a) patients older than 85 years (prior to sending invitations to patients 
for a personal examination) because of the high probability of other co-
morbidities and movement disabilities of a non-parkinsonian character, 
and b) patients with an MMSE score below 23 points. 
Each patient was interviewed three weeks after receipt of the 
invitation. After the interview with a psychologist (T.D.), one neurologist 
from the research team (E.H.) conﬁ  rmed the initial diagnosis of PD and 
assessed each patient’s disease severity using the Uniﬁ  ed Parkinson’s 
Disease Rating Scale (UPDRS Version 3.0) [23]. The patient’s cognitive 
status was assessed using the Mini-Mental State Examination (MMSE) [24]. 
The structured interview consisted of questions on the patient’s medical 
history and subjective feelings that were not part of the questionnaire. 
Sociodemographic data were derived from questionnaires ﬁ  lled in by 
patients themselves and data about antiparkinsonian therapy from 
medical records. 
Participation in the research was voluntary. The study was conducted 
only after informed consent was obtained from the patients prior to the 
interview. The local Ethics Committee of the University Hospital in Kosice 
approved the study in Kosice on 17 December 2002.
Measures
Disease severity
The Uniﬁ   ed Parkinson’s Disease Rating Scale (UPDRS) is a tool for 
assessing disease severity in patients with Parkinson’s disease and consists 
of four parts: mentation and mood (Part 1), activities for daily living (Part 
2), motor function (Part 3) and complications from dopaminergic therapy 
(Part 4), including motor ﬂ  uctuations and dyskinesias. Parts 1, 2, and 4 
are interview-based, while Part 3 is based on a clinical examination by a 
health care professional and represents the patient’s condition at the time 
of examination. A neurologist scores patients on a scale from 0 to 176, 
where a higher score is indicative of increased disease severity [23].
Type D personality
The DS-14 was used to assess Type D personality and its two constituent 
subscales, negative affectivity (NA) and social inhibition (SI). NA means 41
the tendency to experience negative emotions, like anger, dysphoria, 
irritability, hostile feelings, depressed affect and anxiety. The SI scale 
covers discomfort in social interactions, reticence and lack of social 
poise [25]. The construct of Type D personality is stable when compared 
to the gender effect [20, 25, 26, 27]. Subjects rated these aspects of their 
personality on a 5-point Likert scale ranging from 0=false, 1=rather false, 
2=neutral, 3=rather true to 4=true. The NA and SI scales were then scored 
as continuous variables (range 0-28). A cutoff of 10 on both scales was 
used to classify subjects as Type D (NA ≥ 10 and SI ≥ 10) [25]. Cronbach’s 
alpha in the original study was 0.88 for NA and 0.86 for SI. In the current 
study, DS-14 showed a good internal consistency (with Cronbach’s alphas 
of .77 for NA and .76 for SI).
Quality of  life 
The Parkinson’s Disease Questionnaire-long form (PDQ-39) is a disease-
speciﬁ  c instrument developed for measuring health-related quality of 
life in patients with Parkinson’s disease. Its 39 items are divided into 8 
scales: mobility (10 items), activities of daily living (6 items), emotional well-
being (6 items), stigma (4 items), social support (3 items), cognition (4 items), 
communication (3 items) and bodily discomfort (3 items). Respondents 
selected answers to each question ranging from never (0), occasionally 
(1), sometimes (2), often (3) and always (4). Each scale and the summary 
index were then adjusted to have a range from 0 (no problem at all) to 
100 (maximum level of problem) [28]. The summary index represents the 
overall QoL. 
Statistical analysis 
The Statistical Package for the Social Sciences (SPSS 14.0.1.) was used to 
analyze the data. Firstly, independent sample t-tests were conducted to 
assess differences between genders in disease severity, disease duration, 
age, Type D, NA and SI. In addition, the difference of proportions test 
(CIA) was used to assess gender differences in partnership and education 
[29]. Next, multiple linear regression analyses were used to assess the 
contribution of the independent variables (disease severity (UPDRS), 
disease duration, age, and the Type D personality trait) on the explained 
variance of the dependent variables (dimensions of the PDQ-39 and 
overall QoL). Thirdly, an identical regression analysis was performed for 
males and females separately. Finally, regression analyses for males and 
females were performed separately with the NA and SI scales instead of 
Type D.42 CHAPTER  3
Results
Descriptive statistics
Out of 512 patients with Parkinson’s disease, 160 agreed to participate 
and ﬁ  lled in the questionnaires. Non-respondents included 41 patients 
who refused to participate and 311 who did not respond to the invitation. 
Seven patients were excluded after the personal interview because of the 
exclusion criteria. The ﬁ  nal sample thus consisted of 153 patients (29.8%). 
Non-respondents differed signiﬁ  cantly from the analyzed group in age 
(mean difference 1.69 yrs., SE=.87; t=-1.95; 95% CI .010 – -3.39) and there 
were signiﬁ  cantly more women than men among the non-respondents 
(difference -0.0110; SE=.041; 95% CI -.091 – .069) (Table 3.1).
All patients used antiparkinsonian therapy according international 
guidelines [30,31]. Twelve percent of patients used only L-dopa, 24% used 
only dopamine agonists, 25.3% used L-dopa in combination with COMT 
inhibitors, 20% used L-dopa with dopamine agonists and 16% used a 
combination of L-dopa, a COMT inhibitor and dopamine agonists.
Both questionnaires, PDQ-39 and DS-14, showed good internal 
consistency. Cronbach’s alphas in the present study for PDQ-39 were as 
follows: .93 (mobility), .91 (activities of daily living), .82 (bodily discomfort), .86 
(emotional well-being), .87 (stigma), .75 (social support), .69 (cognition) and .79 
(communication). Cronbach’s alpha for DS-14 in the original study was 0.88 
for NA and 0.86 for SI. In the current study, these ﬁ  gures were .77 and  .76, 
respectively.
Model of predictors of QoL     
Multiple regression analyses were performed in order to identify how 
much the variance of the dependent variables (mobility, activities of daily 
living, emotional well-being, stigma, social support, cognition, communication, 
bodily discomfort and the summary score for the PDQ-39) may be explained 
by Type D and the selected disease and demographic variables. 
Type D was strongly associated with all dimensions except mobility, 
activities of daily living and bodily discomfort, which were explained only by 
UPDRS. Being Type D was associated with a high score in these dimensions 
(meaning worse QoL). After UPDRS, Type D also explained most of the 
variance in the overall model of QoL for PD patients. (Table 3.2)43
Table 3.1 Characteristics sample – means and standard deviations (SD) of demographic and study 
variables.
Males Females Total sample
Number of subjects (%) 79 (51.6) 74 (48.4) 153 (100)
Mean age in years (SD) 68.5 (9.2) 67.3 (9.3) 67.9 (9.3) ns#
Mean disease duration (SD) 7.7 (5.7) 7.4 (5.8) 7.5 (5.8) ns#
Disease severity – UPDRS (SD) 38.8 (22.2) 34.9 (18.7) 36.9 (20.6) ns#
Quality of Life – PDQ-39 total (SD) 444.3 (128.9) 475.9 (119.2) 459.5 (124.9) ns#
Married or living with a partner (%) 66 (83.5) 38 (51.4) 104 (68) 95% CI 
8.2-46.2 
Education elementary (%) 22 (27.8) 30 (40.5) 52 (34) ns α
secondary (%) 44 (55.7) 40 (54.1) 84 (55) ns  α
university (%) 13 (16.5) 4 (5.4) 17 (11) 95% CI 
1.4-20.7
Type D personality (%) 39 (49.4) 41 (55.4) 80 (52.3) ns α
Negative affectivity (SD) 12.6 (6.1) 13.6 (6.3) 13.1 (6.2) ns#
Social inhibition (SD) 13.0 (5.7) 14.0 (6.5) 16.5 (6.1) ns#
Abbreviations: SD – standard deviation, ns - not significant
# t-tests
α difference of proportion test
Gender differences in predictors of QoL
UPDRS was an important predictor in the overall model of QoL in both 
genders and had a relatively high explanatory power particularly in the 
models of mobility and activities of daily living. In cognition UDPRS was the 
only important factor, explaining 22% of the model’s variance in women. 
The factors selected for the model were not relevant for explaining the 
models of stigma, social support and bodily discomfort in either gender, nor 
the model of communication in women. 
Type D explained emotional well-being in both genders. Among men, 
Type D was an important factor in the models of stigmatization by illness, 
cognition and communication but played no role in these models among 
women. Type D personality did remain an important part of the model in 
the overall QoL score, however. 
In Table 3.3 both scales contributing to Type D are also analyzed 
separately. NA was found to be signiﬁ  cantly associated in both genders 
with emotional well-being. In men it was the only illness-related factor for 
feeling stigma. In women, a higher NA explained the higher dissatisfaction 
with social support. For overall QoL, NA explained 13.2% (P<0.001) of the 
variance in males and 9.3% (P<0.01) of the variance in females. SI also 
explained a maximum of 5.5% (P<0.05) of the variance in communication in 
men and 7.3% (P<0.05) stigma in women.44 CHAPTER  3
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Discussion  
The Type D construct is a relevant factor for assessing quality of life in 
patients with Parkinson’s disease. Having a Type D personality was, after 
disease severity, the second most important part of the model of overall 
QoL in PD patients and is related to their worse score in the dimensions 
of emotional well-being, stigma, social support, cognition and communication, in 
particular. With the exception of cognition, all other domains associated 
with Type D are connected with social functioning or social life. Although 
both Type D scales deﬁ  ne negative feelings and attitudes of the individual, 
which in turn negatively determine social behavior [25], it may be stated 
that people with a higher score in Type D are generally less satisﬁ  ed with 
various aspects of their social life. Type D persons are well aware of their 
level of emotional distress as indicated by high scores on distress measures. 
It is possible that distress mediates the inﬂ  uence of Type D personality 
on QoL. Therefore, repressive coping would also have to predict clinical 
events beyond the effect of Type D personality [32,33].
Even though the genders did not differ in the distribution of the 
Type D personality in the analyses, the impact of Type D personality on 
quality of life is apparent by gender. In the model of overall quality of 
life, NA appeared to be important for both genders, contrary to SI, which 
does not play a role in the model. A higher score in NA was associated 
with a worse score in the dimensions of stigma and cognition in men, 
while in women it was associated with a worse score in social support. In 
both genders, NA explained the variance in emotional well-being. SI was 
important in the model of communication in men and stigma in women. In 
women, personality traits like NA or SI seemed to play a less important role 
in comparison with men, in contrast to gender differences in personality 
traits reported in a study by Martin and Kirkcaldy (1998). In their study, 
females scored generally higher in neuroticism compared with males [34]. 
In line with the results of this paper, it can be hypothesized that models of 
QoL for men and women are composed of different variables.
Only a few studies have investigated gender differences in PD 
patients. These studies compared both groups mainly with regard to 
sociodemographic characteristics, socioeconomic status and disease 
duration [8,35]. In one cross-sectional study of PD patients [36], no 
differences in PDQ-39 scores between men and women were found, and 
the authors found that neither age nor gender had a signiﬁ  cant impact on 
quality of life in PD patients studied. On the contrary, being older, being 
female and belonging to lower socioeconomic groups are associated with 
poorer quality of life in the general population [36,37]. 
Our results can be compared with those from a study of older 
adult couples by Robb et al. (2003), in which neuroticism and extroversion 47
emerged as moderators of the association of stressors and the husband‘s 
subjective well-being [38]. The gender aspect of QoL appears to be an 
important topic for further research, which could go deeper into the 
psychological differences between men and women. 
A limitation of this study was the relatively low response rate, which 
may have an impact on generalization of the results to the total population 
of PD patients. Non-respondents were older than respondents, so it 
may be supposed that they refused to participate in the study because 
of serious motor complications found in the higher stages of PD and 
due to the need for help from their social surroundings. Regrettably, we 
have no information about disease duration and disease severity of non-
respondents. 
The analysis presented in this paper explains just part of the variance 
of the QoL of patients with PD. In several models, e.g. communication, 
bodily discomfort or social support, differences between genders existed in 
the adjusted explained variance. These differences in the models suggest 
possible differences in the main variables in both genders, which suggests 
that the model of QoL is composed of different variables for each gender. 
Personality traits seem to be one of the possible ways to explain these 
differences. 
More knowledge about the association of negative affectivity, 
social inhibition and quality of life in PD patients may give us a clearer 
view of patient complaints in the case of worsening quality of life. It is 
important in further research to unravel the relationship between Type 
D, distress and QoL. In addition, the gender aspect of QoL appears to be 
an important topic, contributing to our knowledge about psychological 
differences between men and women. Consequently, coping styles and 
self-management skills in both genders might also differ, as has been 
shown in several other studies [39,40]. Because of the possible different 
needs of men and women, psychological intervention programs may need 
to be different as well.
This study concludes that the Type D personality and its scales 
of negative affectivity and social inhibition are important factors that 
may play an important role in assessing quality of life in patients with 
Parkinson’s disease. 
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Abstract 
Objectives: This systematic review focuses on the role of the intensity of 
fear in patient’s delay in cancer and in myocardial infarction.
Methods: In a search of literature published between 1990 and June 2009, 
161 articles were found. After the use of inclusion and exclusion criteria, 
11 articles in cancer and 4 articles in myocardial infarction remained. 
Results: High levels of fear are associated with earlier help-seeking in 
both diseases; for low levels of fear the picture is unclear.
Conclusion: The level of fear is an important factor which should be taken 
into account when facilitating help-seeking by patients.
Introduction
An early visit to the physician is sometimes a matter of life or death. The 
question is, what is late and what is ‘in time’ in health care? Early help-
seeking has an impact on the success of treatment related to the moment of 
intervention for a particular disease. For example, the prognosis for breast 
cancer and melanomas is better for patients if the problem is diagnosed 
within 3 months [1]. Thrombolytic treatment for heart attack is more 
effective when given within 2 hours [2], though it works best in the ﬁ  rst 60 
minutes [3]. To achieve a reduction in mortality from the most prevalent 
diseases among people of working age (men and women from 15 to 64 
years of age [4]) in European countries (acute myocardial infarction (AMI) 
and cancer), a better understanding of the reasons for late and delayed 
diagnosis and consequent treatment in patients with potential symptoms 
of these diseases is required [5,6]. 
Patient’s delay is most frequently described as the “length of delay 
between the onset/discovery/recognition of signs and symptoms and 
a patient’s ﬁ  rst visit to a health care/medical provider” [7,8], but more 
simple descriptions like “time to ﬁ  rst presentation of signs or symptoms 
to a physician” can be found as well [9,10]. Also, the terms ‘help-seeking 
delay’ or ‘help-seeking behavior’ are frequently used in the literature as a 
synonym for ‘patient’s delay’. 
In many studies patient’s delay is associated mainly with 
sociodemographic factors such as gender, age, socioeconomic status 
(SES) or marital status, though the ﬁ  ndings are equivocal. The strongest 
evidence exists for longer patient’s delay being associated with age and 
SES (without regard to diagnosis). Older people [1,11-13] and people from 
low SES groups [5,12,14,15] had a tendency to hesitate in consulting an 
expert. The relationship between gender and patient’s delay is not so 
strong and varies from ‘women had a higher tendency to delay’ (in cases 
of AMI and cases of melanoma) [11,14,16-18] to ‘there is no correlation 53
between patient’s delay and gender’ (in cases of AMI) [19, 20]. The 
same holds true for education; several studies conﬁ  rmed the association 
between a lower level of education and a greater tendency to hesitate in 
seeking help [5,13,18,21], but approximately the same number of studies 
refuted this association [8,22-24].
Not only sociodemographic factors inﬂ  uence patient’s delay; clinical 
variables also appear to be important for making a decision on accessing 
health care. In many cases, previous medical history has an opposite effect 
on an early visit to surgery or emergency center. Women with a personal 
history of benign forms of breast cancer delayed longer in comparison 
with women without a history of a benign disease [5,25]. It was also found 
that patients with typical symptoms of a certain disease seek help sooner. 
Persons who identiﬁ  ed symptoms correctly as originating from the heart 
received help one hour earlier compared to those who attributed their 
pain to other parts of the body [16,18]. Results from breast cancer studies 
also conﬁ  rm this association between typical symptoms of the disease 
and earlier consulting with an expert. Women delayed longer when initial 
breast symptoms did not include a lump [23] compared to women who 
detected a breast lump, the latter group waiting signiﬁ  cantly less time 
[26]. An important factor for decision-making is knowledge. Patients who 
came earlier to the emergency room had more knowledge about the 
cardiovascular system and cardiac symptoms, more appropriate behavior 
and fewer risk factors when compared with the group of patients who 
delayed for more than 1.5 hours [22]. This was conﬁ  rmed by the ﬁ  nding 
that knowledge is a stimulating factor in the decision-making process 
about having a disease [27,28]. 
Apart from sociodemographic and clinical variables, psychological 
factors may also play a role in patient’s delay. Several clinical studies 
mentioned fear as an important psychological factor associated with 
motivation for treatment or patient’s delay [29-31]. According to the 
deﬁ  nition, fear is the emotional reaction to a speciﬁ  c, identiﬁ  able and 
immediate threat such as a dangerous animal or an injury, and it has 
a protective function associated with the ﬁ  ght or ﬂ  ight response [32]. 
Clinically, the terms fear and anxiety are frequently used interchangeably 
[30]. However, there are differences between these variables from a 
psychological point of view. Anxiety is a form of negative emotions closely 
related to fear and is deﬁ  ned as unspeciﬁ  ed fear with no clear focus [33]. 
Whereas fear motivates an individual to engage in defensive behaviors, 
anxiety is associated with preventive behaviors, including avoidance, 
and may have higher intensity than actual fear. For these reasons, ‘being 
anxious’ was deﬁ  ned for the purposes of this paper as having a higher 
intensity than ‘having fear’.
The connection of fear with patient’s delay was well described in 
the Leicester review, where the authors identiﬁ  ed two types of fear (fear 54 CHAPTER  4
of embarrassment and fear of cancer) in a review of studies in different 
types of cancer [34]. In order to complete the variances of fear, fear of 
pain may also be included, a fact relevant mainly for diseases associated 
with muscular injuries or delay in the rehabilitation process [31]. Feelings 
such as worry, fear and anxiety can be elicited by symptom-induced 
pain or discomfort, presumed diagnosis and anticipated consequences 
of treatment, as well as by coping failures and reinterpretations of the 
illness condition [35]. Fear appears to be an important psychological 
factor in delay, and its intensity may have an inﬂ  uence on early arrival 
to a health care professional. Studies analyzing the association between 
patient’s delay and fear in patients with cancer and AMI were selected for 
the review, because these two diseases are the two main causes of death 
in European countries [36]. The aim of this paper is to explore the role 
of the intensity of the perception of fear and anxiety in the help-seeking 
process in patients with a slow, progressive disease and in those with an 
acute disease.
Methods 
In June 2009, the electronic databases MEDLINE and PsychINFO were 
searched for articles meeting the following inclusion criteria: 1) original 
papers on cancer or AMI, 2) written in English, 3) from the search 
period 1990 until June 2009 and 4) containing the key words ‘patient’s 
delay’ or ‘help-seeking behavior’ or ‘treatment-seeking behavior’ or 
‘treatment seeking delay’ or ‘patient acceptance of health care’ and ‘fear’ 
or ‘anxiety’. 
Two reviewers (TD and JPvD) independently assessed the studies 
that were identiﬁ  ed during the screening based on information obtained 
from the title and the abstract of the publications from the ﬁ  rst search 
strategy. When discrepancies appeared, the papers were independently 
assessed by a third reviewer (JWG). After the ﬁ  rst search, both reviewers 
read the full text of the selected 15 articles. 
For this systematic review we adopted and modiﬁ  ed  criteria 
from existing quality assessment lists [37, 38]. Two reviewers (TD and 
JPvD) assessed the quality of the publications as positive (+), negative 
(-) or unknown (?) based on the information provided in the article. 
Disagreements between reviewers were discussed during a consensus 
meeting. The following four quality criteria were chosen for evaluating 
the publications:
I. deﬁ  nition and operationalization of patient’s delay – patient’s 
delay was deﬁ  ned exactly using a disease-speciﬁ  c cutoff point 
which divided the sample into delayers and non-delayers (+), or 
patient’s delay was deﬁ  ned as a continuous variable (-),55
II. deﬁ  nition and operationalization of fear or anxiety – fear and 
anxiety were operationalized and deﬁ  ned (+), or they were not 
clearly deﬁ  ned (-),
III. reliability of measurements of fear or anxiety – using validated 
measurements for fear and anxiety (e.g. HADS, STAI-T, SCID, 
LEDS etc.) (+), qualitative study (+), assessing fear or anxiety 
only from self-reporting of patients or non-validated scales (-), 
IV. sample size – adequate sample size for the statistical method 
used (+), inadequate sample size for the statistical method used 
(-)
V. statistical analyses – using t-tests, chi-square, correlations, 
regression analyses etc. for (+) or using descriptive statistical 
methods (means and percentages) (-) for assessment of the 
relationships between patient’s delay and intensity of fear.
 
For each study a quality score was calculated. The paper was rated as 
‘strong evidence’ when it had an adequate sample size, used validated 
measurements and reported statistically signiﬁ  cant differences in relation 
to the patient’s delay or fear or used appropriate analytic techniques 
(qualitative studies). Papers which had an adequate sample size and 
used a rigorous methodology to ascertain data but used only descriptive 
statistical methods were rated as having a ‘moderate’ level of evidence. 
Papers which used inappropriate methods of collecting relevant data about 
patient’s delay or fear and used insufﬁ  cient analysis were considered as 
‘insufﬁ  cient’. 
Results 
Using the ﬁ   rst search strategy 158 articles were found. Additional 
screening based on authors detected another 16 articles which were not 
included in the MEDLINE or the PsychINFO database. Three of the 19 
authors consulted also mailed a reference to 3 other articles related to the 
topic of patient’s delay. Thus the total number of articles found was 177.
From these 177 articles, 162 were excluded because: they contained 
irrelevant content; involved studies of children and adolescents; were case 
reports; were books or book chapters; and because they:
-  focused only on the association between patient’s delay and 
progression of disease or the effectiveness of treatment; 
-  reported on the effectiveness of educational programs for 
reducing patient’s delay;
-  concentrated only on the association of patient’s delay with 
sociodemographic factors (e.g. age, gender, educational level, 
occupation);56 CHAPTER  4
-  focused only on measuring the time from ﬁ  rst signs until ﬁ  rst 
contact with a medical doctor without any further explanation.
The process of applying these criteria is shown in Figure 1; 15 articles 
remained for review. 
 
Figure 4.1  Flow diagram of the selection process 
Disagreement occurred mainly because of reading errors and differences 
in the interpretation of the list of criteria, but after the consensus meeting 
no disagreements persisted. The third reviewer was not asked for a ﬁ  nal 
decision.
Quality assessment
Only one of the ﬁ  fteen selected studies was rated as ‘insufﬁ  cient’. Eleven 
were considered as having a ‘moderate’ level of evidence and three were 
rated as studies with a ‘strong level of evidence’. (Table 4.1)
 
Computerized database search 
using search terms 
158 studies identified
16 other citation in articles
3 articles sent by authors 
Final result: 177 articles
162 articles excluded 
15 articles met the 
inclusion criteria for the 
review 57
Table 4.1 The ratings of the 15 studies 
Study, reference Disease  I II III IV V Evaluation of the study
Mor et al., 1990 cancer + - - + - 2/5 M*
Burgess et al., 1998 cancer + ? - + + 3/5 M
Burgess et al., 2000 cancer + + + + + 5/5 S*
Nosarti et al., 2000 cancer + - - + - 2/5 M
Brochez et al., 2001 cancer - - - + + 2/5 M
de Nooijer et al., 2001a cancer + + + - - 3/5 M
de Nooijer et al., 2001b cancer + + + - - 3/5 M
Burgess et al., 2001 cancer + +-+- 3 / 5 M
Meechan et al., 2003 cancer - + + + + 4/5 S
Rozniatowski et al., 2005 cancer - + + + + 4/5 S
Ristvedt et al., 2005 cancer - + + - + 3/5 M
Dracup et al., 1997 AMI + - - + + 3/5 M
McKinley et al., 2000 AMI - - - + - 1/5 I*
Kentsch et al., 2002 AMI + - - + - 2/5 M
Moser et al., 2005 AMI - - - + + 2/5 M
*S – Strong level of evidence; M – Moderate level of evidence; I - Insufficient level of evidence; Quality 
criteria: I - definition and operationalization of patient’s delay – patient’s delay was defined exactly using 
disease specific cut-off point which divided sample on delayers and non-delayers (+), or patient’s delay was 
defined as continuous variable (-); II - definition and operationalization of fear or anxiety – fear and anxiety 
were operationalized and defined (+), or they were not clearly defined (-); III - reliability of measurements 
of fear or anxiety – using validated measurements for fear and anxiety (e.g. HADS, STAI-T, SCID, LEDS etc.) 
(+), qualitative study (+), assessing fear or anxiety only from self-reporting of a patients or non-validated 
scales (-); IV - sample size – adequate sample size to the used statistic method (+), inadequate sample size 
to the used statistic method (-); V - statistical analyses – using t-tests, chi-square, correlations, regression 
analyses etc. for (+) or using descriptive statistic methods (means and percentages) (-) for assessment of 
the relationships between patient’s delay and intensity of fear.
Study characteristics
The characteristics of the studies are presented in Table 4.2 Twelve of the 
15 selected studies addressed some form of carcinoma (5 on breast cancer, 
1 on cutaneous melanomas, 3 on patients with various types of carcinoma, 
1 on rectal cancer and 1 on head and neck cancer) and 4 looked at acute 
myocardial infarction. 
In the selected papers information about patient’s delay was obtained 
from structured or semi-structured interviews with patients or from 
medical records. The questionnaires contained parts in which the patients 
were asked about delay and the reasons for delay [23, 39, 40], or the data 
about delay was obtained from medical records [15,26,28, 41]. Measuring 
the concept of fear varied in the selected articles from spontaneous 
sentences from patients about their fear to standardized measures, 
where fear was expressed in numbers. Although reliable, validated 58 CHAPTER  4
and standardized measures to assess fear or anxiety are widely used in 
diagnosis and research (such as the Hospital Anxiety and Depression Scale 
(HADS), State-Trait Anxiety Inventory – Trait scale (STAI-T), the Structured 
Clinical Interview (SCID), the Response to Symptoms Questionnaire and 
the Bedford College Life Events and Difﬁ  culties Schedule (LEDS), such 
measures were used in only six of the studies [15,28,42-44]. In eleven of 
the ﬁ  fteen analyzed studies, expressions of patients were investigated 
using a few items from a larger, non-standardized questionnaire or a 
semi-structured interview. In addition to standardized questionnaires, 
several authors also used qualitative measures covering many aspects of 
various domains of the patient’s life. They offer a place for spontaneous 
expressions from the patient’s point of view. 
How does the intensity of fear inﬂ  uence patient’s delay?
Words which described the intensity of fear varied in the reviewed studies 
from ‘being worried’ to ‘have a fear’, ‘be anxious’, ‘in panic’ or ‘feel death 
anxiety’. This sequence reﬂ  ects the intensity of the emotion of fear.  
Cancer
Being only ‘worried’ by the ﬁ  rst signs of disease is not enough stimulus 
for seeking help in patients with cancer. It appears that patients who were 
worried tended to have longer patient’s delay than those who were not 
worried, although the difference were not statistically signiﬁ  cant (p=0.07) 
[40]. But the same authors also found that patients who were worried 
about their lesion more frequently consulted a dermatologist than those 
who were not anxious at all (p=0.03). It can be hypothesized that being 
worried has no impact on the decision-making process to visit a specialist 
for the ﬁ  rst time, but that it does have an impact on the patient’s wish to 
be treated. 
Results of the studies on ‘having fear’ are contradictory. In patients 
with different types of carcinoma, 17% of the delayers reported fear 
of discovering the cause of their symptoms as the reason for delaying. 
Delayers with breast cancer mentioned this reason more often than 
patients with lung or colorectal carcinoma (20.7% vs. 10.5% and 16%) 
[39]. It was also found that women who expressed more fear about the 
consequences of diagnosis and the treatment of the disease delayed longer 
[45]. In a different study, those who delayed were those who reported 
less fear after discovering the ﬁ  rst symptoms of disease (p=0.05); but in 
contrast, in the same sample more psychological distress (as expressed by 
the GHQ-12 scores) was associated with longer delay, especially in those 
who did indeed turn out to have breast cancer [23,46]. In a later analysis 
it was found that the inﬂ  uence of fear on decision making is related to 
various aspects of treatment, the seriousness of the disease, dying or 
leaving relatives behind [47].59
‘Being anxious’ appears to be a factor which stimulates decision-
making in women with breast cancer [46]. This ﬁ  nding was conﬁ  rmed 
in a study which shows that there was a lack of anxiety and depression 
symptoms in patients with large tumor lesions who delayed consultation, 
whereas patients with smaller lesions with a short delay presented high 
levels of anxiety (p=0.00001) [43]. Using a regression model, not having a 
breast lump (β=-0.35, t=-3.30, p=0.0001) and lower initial symptom distress 
(β=-0.32, t=-3.03, p=0.001) were found to be the factors most predictive of 
patient’s delay [26]. However, in other studies, different results were found. 
It was not conﬁ  rmed that being clinically anxious or depressed before or 
around the time of symptom discovery increases the risk of a woman with 
symptoms delaying her presentation for medical attention [42]. Similar 
results were reported in a study by Ristvedt and Trinkaus (2005), in which 
anxiety was measured with a standardized STAI-T questionnaire. Lower 
scores on STAI-T were associated with fewer doctor visits, so it can be 
hypothesized that the level of anxiety has a positive correlation with 
patient’s delay [44]. However, in the same article the authors found that 
people characterized as fearful, shy, tense, and worried had a signiﬁ  cantly 
shorter delay time [44].
Patients who reacted to ﬁ   rst symptoms with ‘panic’ or were 
‘extremely alarmed’ or ‘anxious’ sought medical help or visited the EMS 
within a few hours [27]. The study showed that panic stimulated patients 
into inferring illness from the symptoms and shortening appraisal delay 
as a result.
Acute myocardial infarction
Studies about worries regarding AMI itself were absent, but several 
studies conﬁ  rmed that patients with AMI who delayed seeking assistance 
reported being worried about troubling others with a request for assistance 
(p=0.001) and feared the ﬁ  nancial consequences of seeking help (p=0.02) 
[15,41]. In patients with AMI ‘having fear’ is associated with hesitation in 
seeking help and therefore with longer patient’s delay [45]. Those patients 
with AMI who were least anxious about their symptoms delayed seeking 
medical attention [28]. Short decision time (< 1 hour) was associated in the 
case of AMI with evaluating symptoms as threatening or dangerous and 
causing a feeling of ‘panic’ and ‘death anxiety’ [48].60 CHAPTER  4
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A summary of the ﬁ  ndings is presented in Table 4.3
Table 4.3 Patient’s delay and stages of fear
Results Cancer AMI
Worry worry has no impact on 
patient’s delay
Brochez et al., 2001
Fear fear shortened time of 
patient’s delay
Burgess et al., 1998, 
Nosarti et al., 2000
fear prolonged time of 
patient’s delay
Mor et al., 1990, 
Burgess et al., 2001
Dracup&Moser, 
1997 
McKinley et al., 
2000
Anxiety anxiety shortened time of 
patient’s delay
Nosarti et al., 2000 
Rozniatowski  et al., 2005 
Meechan et al., 2003 
Ristvedt&Trinkaus, 2005
Moser et al., 2005
anxiety prolonged time of 
patient’s delay
Burgess et al., 2000 
Ristvedt&Trinkaus, 2005
Panic/
Death anxiety
panic or death anxiety 
shortened time of patient’s 
delay
de Nooijer et al., 2001  Kentsch et al., 2002
Discussion 
Summary of the main ﬁ  ndings
This paper presents the results of 15 studies which investigated patient’s 
delay with the intensity of fear. Levels of intensity of fear were constructed 
after a detailed reading of the studies. These stages of fear were: ‘being 
worried’, ‘having fear’, ‘being anxious’, ‘being in panic’ and ‘feeling 
death anxiety’. Differences in fear between cancer and AMI patients were 
expected. ‘Being worried’, ‘having fear’, and ‘being anxious’ were mainly 
present in cancer patients. ‘Being worried’ is not enough for seeking 
help with cancer, but it starts the process of internal thinking about the 
possibility of being treated. The emotion ‘fear’ seems to be a factor for 
longer delay, but the decision process in patients experiencing fear was 
also inﬂ  uenced by other factors, such as embarrassment, pressure from a 
patient’s relatives or fear of ﬁ  nancial consequences. ‘Being anxious’ had 
a direct impact on shortening patient’s delay. These emotions were not 
present in the case of AMI, but the feeling of ‘panic’ or ‘death anxiety’ 
present in cancer and AMI was associated with seeking help within a few 
hours of the appearance of the ﬁ  rst symptoms of illness; the impact of this 
type of fear on the patient’s delay was similar in both diagnoses.63
Meaning of the results
The emotion of fear could lead to either help-seeking behavior or to 
delay, depending on the cause of the fear and the way people cope with 
it. The intensity of negative feelings seems to be an important predictor 
of a patient’s help-seeking behavior. Of the deﬁ  ned levels of fear (‘being 
worried’, ‘having fear’, ‘being anxious’, ‘in panic’ and ‘feeling death 
anxiety’), the latter two have a signiﬁ  cantly positive effect on decision-
making in help-seeking behavior. Either the ﬁ  rst two have no inﬂ  uence 
on patient’s delay (worry) or their impact is ambivalent (fear). Although 
there are differences in the onset of both diseases, the emotional reaction 
upon ﬁ  rst signs or symptoms were similar. ‘Having fear’ from treatment, 
from the consequences of diagnose or from bothering others with bad 
feelings slowed help-seeking behavior in cancer and also in AMI. On the 
other hand, when patients feel anxiety or panic, according to the results 
of our review, they seek help sooner in both cases. On this basis, it can be 
expected that people who are more frightened will have a greater chance 
of getting medical help earlier than those without such a strong emotional 
response like in a slow progressive disease - cancer and sometimes also in 
the case of acute myocardial infarction.
The results of this review also show that minimizing the seriousness 
of symptoms was negatively correlated with the intensity of fear, making 
seeking treatment less urgent and producing longer delay. Some authors 
call this phenomenon health-related ‘defensive bias’ [5], ‘optimistic bias’ 
[10] or ‘denial’ [49], which leads to longer patient’s delay. On the other 
hand, these behavioral variables were found to be associated with the 
degree of patient’s understanding of the treatment, which is why some 
authors suggest speaking about ‘indecision’ rather than about ‘denial’ 
[50,51]. 
Another explanation for the connection between fear and patient’s 
delay is that people also differ in their perception of symptoms. Some 
people simply have more symptoms than others, or they differ in the 
sensation they experience from the same symptom [27]. It was observed 
that some people focus on bodily symptoms more intensely than other 
people, leading to increased reports of symptoms [52]. Recognizing pain 
symptoms has a positive effect on rising anxiety and thus on decision-
making in patients with acute myocardial infarction and breast cancer 
[5,16], but this was not proven in all of the studies [35]. The considerable 
difference between acute pain in cases of acute myocardial infarction and 
chronic pain in breast cancer occurring in later stages of the disease also 
has to be taken into account. In the variables of patient’s delay between 
patients with acute myocardial infarction experiencing pain and those 
without pain, no signiﬁ  cant correlations were found [15]. Similar results 
were found in women with breast cancer [26]. 64 CHAPTER  4
Strengths and limitations
This study is the ﬁ  rst which systematically summarizes the inﬂ  uence 
of the intensity of fear in patient’s delay in both a slow, progressive 
disease and in an acute disease. A limitation of this study was that the 
analyzed studies did not use the same instruments for measuring fear 
or anxiety. They varied from standardized instruments like STAI-T, 
HADS or LEDS to information from semi-structured interviews or self-
created questionnaires. Measurement of fear was not the primary aim in 
several analyzed studies; therefore, the authors did not pay such detailed 
attention to analyzing the connection of fear or anxiety with patient’s 
delay. Another limitation of the analyses of fear is that, like in all studies 
examining the relationship between level of fear/anxiety and delay, all 
patients were assessed retrospectively after they had been admitted to the 
hospital. The generalizibility of the results may be limited by a potential 
publication bias towards positive ﬁ  ndings.  
The qualitative evaluation of studies may be also interpreted. Only 
six of the ﬁ  fteen selected articles use validated measurements of fear or 
anxiety. In the remaining cases, fear was not the main aim of the study, 
but it was one of the possible reasons for patient’s delay. In six cases, the 
authors used the patient’s delay as continuous variable in the analyses, 
a fact viewed as a negative factor in this paper. Patient’s delay should 
be interpreted from a disease-speciﬁ  c point of view, which is why it is 
preferable to speak about patient’s delay only in cases when a patient 
comes to a health professional after a certain moment which is related 
to the diagnose. A lack of operationalization of fear or anxiety was 
observed especially in studies where the author did not used validated 
measurements. Patients in these studies just reported fear for various 
reasons, but its intensity or speciﬁ  cation is missing. The results of the 
evaluation of the studies reviewed in this paper should inspire us to be 
more focused primarily on the association between patient’s delay and 
fear and anxiety.
Conclusion
There are two ways of coping with fear – ﬁ  ght or ﬂ  ight. The avoidance 
behavior associated with reduction of fear and anxiety seems to be helpful 
in the short term because of the reduction of negative feelings, but it may 
be counterproductive in the long run [30]. Our data explored the possible 
reasons for patient’s delay. The lack of emotional response on symptom 
discovery can lead to patient’s delay in both AMI and cancer. The level of 
fear evidently inﬂ  uences the decision-making process in patients on help-
seeking and hence, this important factor should be taken into account 
when facilitating help-seeking by patients, and especially in cases of low 
level of fear, encouraging them to seek out medical care. Results of the 
study suggest that fear might not be disease speciﬁ  c and might have a 65
similar impact on the decision making process in acute as well as slow 
progressive diagnoses. Unfortunately, the results needed to clarify this 
point regarding other diseases are missing.  
Knowledge about factors associated with patient’s delay also 
could be used in preparing educational programs. Studies suggest that 
psychological rather than demographic factors are the main predictors 
of delay time [46]. Therefore, information about clinical variables could 
be included in the content of such programs, though knowledge about 
psychological phenomena such as fear and worry can be a more meaningful 
factor affecting their efﬁ  ciency. It was observed that health education about 
cancer mostly tells people how to identify cancer symptoms but provides 
little about the consequences of a cancer diagnosis [45]. Moreover, it was 
shown that when patients are prepared to anticipate an aversive situation, 
they are more likely to cope effectively [15]. Further successful cooperation 
after a patient’s ﬁ  rst visit to the medical doctor is conditioned by doctor’s 
communicative skills and his/her proper counseling [53]. Health programs 
for early help-seeking in case of the appearance of the ﬁ  rst symptoms of 
cancer which are oriented only on information about the disease and not 
on the positive aspects of early diagnosis may increase the fear of a certain 
diagnosis, which may lead to two types of behavior: denying the initial 
symptoms or being hypersensitive to any type of small discomforts in 
the body. Both reactions are strategies with low efﬁ  cacy for coping with 
the disease process and may lead to difﬁ  culties in help-seeking behavior, 
a delay which in turn does not contribute to the reduction in mortality 
aimed for by health policy in most countries. 
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Abstract 
Objectives: The aim of the paper is to explore whether quality of life 
(QoL) in patients with Parkinson’s disease (PD) who delayed in seeking 
help is associated with personality traits. 
Methods: The sample consisted of 142 patients (average age 67.6±9.2 
years; 51.4% men; mean disease duration 7.6±5.9 years). Patient’s delay 
was dichotomized at the cut-off point of 1 year. The Eysenck Personality 
Questionnaire (EPQR-A) was used for measuring extroversion (E) and 
neuroticism (N). Health-related quality of life (HRQOL) was assessed 
using the Thirty-six Item Short Form Health Survey (SF-36) and its two 
summary scores: the physical health component summary score (PHC) 
and the mental health component summary score (MHC). T-tests and 
multiple linear regression analyses were used to analyze the data. 
Results: Increased neuroticism was related to lower scores in PHC and 
MHC in delayers and in non-delayers. Conversely, non-delayers scored 
higher in extroversion, which was associated with better scores in PHC 
and MHC. 
Conclusion: Social interactions, associated with an extrovertly oriented 
personality, can force decision making on help-seeking. Factors 
contributing to early help-seeking behavior in PD patients may result in a 
greater chance of limiting impairment of their quality of life.  
Introduction
Parkinson’s disease (PD) is a chronic progressive neurodegenerative 
disorder inﬂ  uencing many aspects of a patient’s life, primarily in terms 
of mobility and independence. The diversity of symptoms associated 
with PD (e.g. tremor, rigidity, bradykinesia, falls, as well as non-motor 
symptoms like painful spasms, depression, sleep problems and fatigue) 
leads to worse physical, mental and social well-being in comparison with 
people of the same age without symptoms of Parkinsonism, even when 
the disease is treated properly [1-3].  
In the case of life-threatening diseases like stroke, heart attack or 
cancer, seeking medical care sooner has a positive impact on the success 
of treatment [4-6]. The consequence of delay in seeking help for these 
diseases on a patient’s quality of life (QoL) is evident [7,8]. However, there 
is a lack of literature answering the question of whether delay in seeking 
help and treatment is associated with later QoL in chronic diseases such as 
Parkinson’s disease. In PD a patient’s QoL corresponds with the decision 
regarding when to start with drug treatment, whether the decision to take 
a “wait and see” approach or to start with drug treatment immediately 73
upon identifying the diagnosis might make a difference for improving 
the patient’s self-reported QoL [9]. In patients with PD, health-related 
quality of life (HRQOL) is determined mainly by physical mobility and 
progression of the disease [10]. However, quality of life in the elderly can 
be inﬂ  uenced also by non-clinical factors, for example life satisfaction or 
happiness [11,12]. 
The association between patients’ delay and personality traits has 
still not been adequately explained. Many studies on the non-clinical 
factors of patients’ delay have focused mostly on the social, cognitive and 
emotional factors of delay in life threatening diseases, but studies into the 
association between personality traits and patients’ delay are missing. 
The aim of this paper is to explore 1) the relationship between delay 
and quality of life in patients with PD; 2) the association of personality 
traits and quality of life in patients with PD, stratiﬁ  ed by delay.
Methods
Subjects and procedure
The patients for this cross-sectional study were recruited from the databases 
of 4 hospitals and 17 outpatient neurologists in the eastern part of the Slovak 
Republic between February 2004 and February 2006. Neurologists from 
the mentioned institutions diagnosed all patients included in the sample 
as suffering from Parkinson’s disease according to the United Kingdom 
Parkinson’s Disease Society Brain Clinical Criteria [13].
Exclusion criteria were deﬁ  ned as follows: a) patients older than 85 
years because of the high probability of other co-morbidities and movement 
disabilities of a non-parkinsonian character, and b) patients with a Mini-
Mental State Examination (MMSE) score [14] below 23 points. 
Each patient was assessed individually by a neurologist from the 
research team (E.H.) using the Uniﬁ  ed Parkinson’s Disease Rating Scale 
(UPDRS Version 3.0) [15]. A patient’s cognitive status was assessed using 
the MMSE [14]. The structured interview consisted of questions on the 
patient’s medical history and subjective feelings that were not part of the 
questionnaire. Sociodemographic data were derived from questionnaires 
ﬁ  lled in by the patients themselves and data about antiparkinsonian 
therapy from their medical records. 
The study was conducted after informed consent was obtained 
from the patients prior to the interview. Participation in the research was 
voluntary. The local Ethics Committee of the University Hospital in Kosice 
approved the study in Kosice on 17 December 2002.74 CHAPTER  6
Measures
Patient’s delay
The length of patient’s delay was assessed according to two questions: 
‘When did the ﬁ  rst signs of the disease appear?’ and ‘How long did you 
delay the ﬁ  rst consultation with your general practitioner (GP)?’ The answer 
to the latter question was recorded as the number of months. Patients were 
also asked for the approximate date of veriﬁ  cation of PD diagnosis: ‘When 
was the diagnosis of PD conﬁ  rmed?’ In cases of uncertainty, the medical 
records were checked for information regarding the ﬁ  rst consultation of 
a health professional. Because of the intermittent occurrence and slow 
progress of symptoms in the ﬁ  rst phase of the disease, in several cases 
patients who sought medical help within 1 year of the appearance of the 
ﬁ  rst signs and symptoms of the disease were marked as ‘non-delayers’ 
and those over 1 year as ‘delayers’. This period was deﬁ  ned on the basis 
of interviews with patients – when the initial signs were not dramatic, 
people attributed them frequently to ‘stress’. When delaying more than 
1 year after the ﬁ  rst signs appeared, the delay becomes more serious: 
Patients cannot attribute these signs to any cause other than disease and 
should have visited a physician.
Disease severity
The Uniﬁ  ed Parkinson’s Disease Rating Scale (UPDRS) was used in research 
for assessing disease severity in patients with PD. The UPDRS consists of 
four parts, pertaining to: mentation and mood (Part 1), activities of daily 
living (Part 2), motor function (Part 3) and complications of dopaminergic 
therapy (Part 4), including motor ﬂ  uctuations and dyskinesias. Parts 1, 2, 
and 4 are interview-based; Part 3 is based on a clinical examination by a 
health care professional and represents the patient’s condition at the time 
of the examination. A neurologist can score patients from 0 to 176, where 
higher scores indicate increased disease severity [15].
SF-36
The thirty-six item Short Form Health Survey (SF-36) was designed to 
measure health-related quality of life (HRQOL) from the patient’s point 
of view as part of the Medical Outcome Study (MOS). It assesses 8 health 
concepts: a) physical functioning; b) role limitations because of physical 
health problems; c) bodily pain; d) general health perception; e) vitality 
(energy/fatigue); f) social functioning; g) role limitations because of 
emotional problems; and h) general mental health [16]. These scales were 
further combined into 2 summary scores: a physical health component 
summary score (PHC) (subscales a-d) and a mental health component 75
summary score (MHC) (subscales e-h). All item scores are transformed 
into a scale from 0 (poor health) to 100 (optimal health) [17]. Cronbach’s 
alphas for the subscales were .94 for physical functioning, .84 for role 
limitations because of physical health problems, .91 for bodily pain, .69 for 
general health perception, .71 for vitality (energy/fatigue), .74 for social 
functioning, .81 for role limitations because of emotional problems and 
.75 for general mental health. Cronbach’s alphas for the summary scores 
were .87 for PHC and .78 for MHC.
Extroversion and neuroticism 
The Eysenck Personality Questionnaire Revised Abbreviated was used for 
measuring Extroversion and Neuroticism (EPQR-A) [18]. The questionnaire 
was validated in the Czech Republic in a sample of 3565 people [19]. The 
Slovak and Czech languages are very similar. The questionnaire consists of 
24 items divided into 4 subscales: extroversion, neuroticism, psychoticism 
and the lie scale, from which we used extroversion and neuroticism. Items 
are scored on a Yes (=1) / No (=0) basis, and the overall score for each 
subscale ranges between 0–6. Higher scores indicate higher levels of the 
personality traits. Internal reliability found across the samples was .74-
.84 for the subscales of extroversion and .70-.77 for neuroticism [20]. In 
the present study Cronbach’s alpha was .85 for extroversion and .72 for 
neuroticism.
Statistical analysis 
The Statistical Package for the Social Sciences (SPSS 14.0.1.) software 
was used to analyze the data. Summary scores MHC and PHC of SF-
36 as well as the UPDRS score were calculated according the scoring 
algorithm [15,17]. Independent samples were subjected to t-tests to assess 
the differences between delayers and non-delayers in terms of disease 
severity, disease duration, age, MHC and PHC. CIA software was used to 
test the difference of proportions for assessing differences between tested 
groups in partnership and education [21]. Multiple linear regression 
analyses were used to assess the contribution of the independent variables 
– disease severity (UPDRS), age at the time of diagnosis, and extroversion 
and neuroticism – to the explained variance of the dependent variables – 
MHC and PHC – in 2 groups of patients: those who sought help within 
1 year of the ﬁ  rst signs and symptoms appearing and those who delayed 
more than 1 year before seeking medical care. 
Results
Descriptive statistic
Out of 512 patients with Parkinson’s disease, 160 agreed to participate 
and completed the questionnaires. Among the non-participants, 41 76 CHAPTER  6
patients refused to participate and 311 did not respond to the invitation. 
Seven patients were excluded after the personal interview because of the 
exclusion criteria, and 11 questionnaires could not be analyzed because of 
missing data. Non-participants differed signiﬁ  cantly from the analyzed 
group regarding age (mean difference 1.69 yrs., SE=.87; t=-1.95; 95% CI 
.010 – -3.39) and there were signiﬁ  cantly more women than men among 
the non-participants (difference -0.0110; SE=.041; 95% CI -.091 – .069). 
The ﬁ  nal sample consisted of 142 patients (51.4% men, 48.6% women) 
with a mean disease duration of 7.6 years (SD=5.9). Ninety-six patients 
from the sample (67.6%) lived with a partner, and 46 patients (32.4%) were 
widowed, divorced or single. Gender differences appeared in patient’s 
delay; women registered the ﬁ  rst signs of the disease signiﬁ  cantly later 
and more than half of delayers were women. Otherwise there were no 
signiﬁ   cant differences in age, disease duration and functional status 
(measured by UPDRS) between men and women. Delayers and non-
delayers signiﬁ  cantly differed in marital status (70.9% of the non-delayers 
lived with a partner), in disease severity (non-delayers had worse scores 
on the UPDRS) and non-delayers perceived their health status as worse.
Delayers and non-delayers differed regarding age achieved as of the 
date of data collection, but there were no differences in their age at the 
time of providing the diagnosis. In non-delayers there were more patients 
with an elementary education and in delayers there were more patients 
with secondary education. The samples did not differ in the number of 
patients with a university education. Patients who delayed longer had 
signiﬁ  cantly shorter disease duration (p≤0.001) and achieved signiﬁ  cantly 
lower scores on the UPDRS (p≤0.001) than non-delayers. In MHC there 
were no differences between the two groups, but in PHC the delayers 
scored higher (p≤0.05).  
All patients used antiparkinsonian therapy according international 
guidelines [22, 23]. Twelve percent used only L-dopa, and 24% used only 
dopamine agonists. L-dopa in combination with Catechol-O-Methyl-
Trasnsferase (COMT) inhibitors were used by 25.3% of the patients and 
L-dopa with dopamine agonists were used by 20% of the patients. The 
combination of L-dopa, a COMT inhibitor and dopamine agonists was 
used by 16% of the patients from our sample.
Physical and mental quality of life in delayers and non-delayers 
Results of the linear regression are displayed in Table 5.2 In delayers and in 
non-delayers high scores on the UPDRS and neuroticism were associated 
with low scores in PHC and MHC. 77
Table 5.1 Characteristics of the sample by length of delay – means and standard deviations (SD) or N (%) 
on demographic and study variables 
delay < 1 year
(non-
delayers)
delay > 1 year
(delayers)
Total sample
p / 95% CI
Number of subjects (%) 79 (55.6) 63 (44.4) 142 (100)
Gender
Males (%) 47 (59.5) 26 (41.3) 73 (51.4)
Females (%) 32 (40.5) 37 (58.7) 69 (48.6)
Mean age in years (SD) 69.4 (8.6) 65.4 (9.6) 67.6 (9.2) p≤0.01
Mean age at onset signs (SD) 62.5 (11.0) 59.9 (10.7) 61.3 (10.9) ns#
Married or living with a partner (%) 56 (70.9) 40 (63.5) 96 (67.6) -.08; .23 ns α
Education 
elementary (%) 32 (40.5) 15 (23.8) 47 (33.1) .02; .32 α 
secondary (%) 35 (44.3) 44 (69.8) 79 (55.6) -.41; -.10 α
university (%) 12 (15.2) 4 (6.3) 16 (11.3) -.01; .12 ns α
Disease duration (SD) 9.2 (6.4) 5.6 (4.3) 7.6 (5.9) p≤0.001
UPDRS (SD) 43.1 (21.3) 29.1(15.8) 36.9 (20.2) p≤0.001
Personality 
Neuroticism (SD) 2.2 (1.9) 2.7 (1.9) 2.4 (1.9) ns#
Extroversion (SD) 2.6 (2.3) 2.9 (2.2) 2.7 (2.2) ns#
Mental health summary score (SD) 48.7 (16.0) 53.6 (18.8) 50.9 (17.4) ns#
Physical health summary score (SD) 33.6 (18.0) 42.5 (25.5) 37.6 (22.0) p≤0.05
Abbreviations: SD – standard deviation, ns - not significant; # t-tests;  difference of proportion test
In non-delayers extroversion was an important part of the model 
explaining MHC. A higher score in extroversion explained 11.2% of the 
variance in MHC – that is, being more extroverted means a better score in 
MHC. Age at onset, education and disease duration up to the time of the 
research were not relevant variables in either model.
Table 5.2 Multiple regression analyses of mental and physical summary score in delayers and non-delayers 
with disability (UPDRS), age, disease duration, education, extroversion and neuroticism 
Mental summary score Physical summary score
Variables delay < 1 year delay > 1 year delay < 1 year delay > 1 year
UPDRS -.39*** -.31* -.62*** -.55***
age at onset signs .04 -.09 .01 -.09
education .04 .07 .16 .12
disease duration .10 -.02 .19 -.01
extroversion .32** .12 .07 -.09
neuroticism -.36** -.40** -.22* -.27*
Model
Adj.R2=.36
F-value=7.0***
Adj.R2=.41
F-value=5.0***
Adj.R2=.39
F-value=7.9***
Adj.R2=.49
F-value=8.7***
*p≤.05, ** p≤.01, *** p≤.001; displayed values are Beta’s 78 CHAPTER  6
Discussion
Patients with PD who came earlier to see a health care professional had a 
signiﬁ  cantly lower physical quality of life than delayers, but they did not 
differ in their mental quality of life. It is supposed, that delayers were less 
affected by the disease which might have been the reason for the longer 
delay, and also for the higher physical quality of life.
In both models analyzing MHC and PHC, neuroticism, after disease 
severity, contributed substantially to the models for non-delayers and 
delayers. Neuroticism was negatively related to both the mental health and 
the physical health component of the HRQOL. It can be hypothesized that 
neuroticism is a reaction to getting a chronic and quality-of-life decreasing 
disease such Parkinson’s disease. This idea is supported by the ﬁ  ndings 
of a large British study [24]. The feelings of anxiety and worry are rather 
stable components of neurological diseases in comparison with healthy 
control samples. A high score in neuroticism was in several studies also 
mentioned as a factor closely related to depression, which is one of the 
symptoms of PD patients, but it is also associated with other neurological 
diseases [24-26]. 
Extroversion was associated with the prediction of a better score 
in MHC in non-delayers. Extroverted people are sociable; they prefer 
changes, crave excitement and act impulsively [27]. Several studies found 
that the possibility of sharing feelings with somebody has a signiﬁ  cant 
impact on the decision to consult a specialist. In one British study, among 
the important factors associated with longer patient delay was not 
disclosing the discovery of the breast symptom immediately to someone 
else and seeking help only after being prompted by others [28]. A positive 
correlation was found between ‘asking others for advice’ and the decision 
to visit a specialist early also in studies from various countries [29,30]. This 
association was conﬁ  rmed indirectly by a French study of 100 patients 
with head and neck cancer, where 43% of the patients who lived alone 
and 21% of those who lived with a partner delayed consultation. In the 
same study ‘living with a partner’ correlated with higher anxiety, which 
implies that anxiety caused by the partner’s observations may have been 
the motivating factor that induced the patients to seek consultation earlier 
[31]. The other person could facilitate the recognition of the potential 
seriousness of the situation and the decision to seek medical advice 
[32]. This corresponds with the results of Smith and colleagues (2005), 
who mentioned that others noticed changes, such as weight loss and 
lethargy, and they made the connection between symptoms and illness 
for the patient, who discussed his or her vague symptoms with them [33]. 
Consequently, it can be hypothesized, that extroverts have more social 
interactions which can lead to earlier help-seeking behavior.  
A limitation of this study was the relatively low response rate, which 79
may have an impact on generalization of the results to the total population 
of PD patients. Non-respondents were older than respondents, and a 
possible reason for refusing participation in the study could be the presence 
of more serious motor complications associated with higher stages of PD 
and the increasing need for help from their social surroundings compared 
with the participants. We are regrettably missing information about 
disease duration and disease severity in the non-respondents.  
Our study showed that personality traits, especially extroversion 
and neuroticism, are closely associated with HRQOL in patients with PD. 
More sociable patients have a greater chance of getting medical help sooner 
than patients who are isolated. Disease severity and the number of social 
interactions associated with an extrovertly oriented personality seem to 
be important for decision-making. It is also evident that neuroticism 
is associated with a decrease in overall perception of quality of life in 
patients with Parkinson’s disease, but it is not associated with patient’s 
delay. Recent treatment of PD patients is primarily concerned with the 
improvement of motor functioning and on symptoms that lower quality 
of life decreasing [34]. Currently, treatment options for neurodegenerative 
diseases, including parkinsonism, are limited and mainly affect only the 
symptoms of a disease and have no signiﬁ  cant disease-modifying effect 
[35]. Early help-seeking behavior will be important in the future, when a 
neuroprotective therapy is developed for patients having PD [36]. Under 
such conditions, seeking help sooner will mean better chances to limit the 
progress of the disease in its early phase, when the impact of the disease 
on a patient’s quality of life is not yet very signiﬁ  cant.  
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Abstract 
Background: The present study examines the role of Type D personality, 
anxiety and depression in quality of life (QoL) in patients of two chronic 
neurological diseases – Parkinson’s disease (PD) and multiple sclerosis 
(MS). 
Methods: This cross-sectional study included 142 PD patients (73% males; 
mean age 67.6±9.2 years) and 198 patients with MS (32.3% males; 38.4±10.8 
years). Multiple regression analyses were used to analyze the association 
of UDPRS (PD patients) or EDSS (MS patients), Type D personality (DS-14) 
and anxiety and depression (HADS) with the physical (PCS) and mental 
summary (MCS) of QoL, as measured by the SF-36.
Results: In PD patients, Type D was signiﬁ  cantly associated with MCS 
only; in MS patients Type D was signiﬁ   cantly associated with both 
dimensions - MCS and PCS. After adding anxiety and depression, the 
importance of Type D for the QoL model dramatically decreased. Anxiety 
and depression were strongly associated with lower scores in MCS and 
PCS in both PD and MS patients. 
Conclusions:  The actual mood of PD and MS patients – the level of 
anxiety or depression – might have a greater impact on patients’ QoL than 
their personality. Further longitudinal research should focus on how the 
pathway consisting of personality traits, anxiety and depression, and QoL 
might be constructed.
Introduction
The major clinical symptoms of Parkinson’s disease (PD) and multiple 
sclerosis (MS) signiﬁ  cantly affect a patient’s quality of life. Symptoms 
associated with PD are tremor, rigidity, bradykinesia and falls, as well 
as non-motor symptoms like painful spasms, depression, sleep problems 
and fatigue [1,2]. Multiple sclerosis (MS) is a disorder of the central 
nervous system (brain and spinal cord) caused by demyelinations in the 
white matter of the central nervous system. It is marked by lack of muscle 
coordination, muscle weakness, speech problems, paresthesia, and visual 
impairments [3,4]. MS is characterized by recurrent attacks of neurological 
symptoms followed by a remission [4]. Other forms of MS are secondary 
progressive, primary progressive, progressive relapsing and the malignant 
course of the disease [5]. In both diseases, the symptoms lead to worse 
physical, mental and social well-being in comparison with people of the 
same age without symptoms of Parkinsonism or MS [2,6-10]. 
Mood disorders, especially depression, are among the clinical 
symptoms of both diseases. In PD patients, the prevalence of depression 
ranges from 20% to 40% [11,12], while depression affects 27-54% of MS 
patients [13,14]. Both diseases are often associated with higher scores in 85
anxiety [15,16]. A recent study by Goretti and colleagues clearly presented 
that depression had a negative impact on all QoL domains and anxiety on 
the mental domains in MS patients [17]. Anxiety and depression, even at 
moderate levels, were also positively linked with poor QoL in studies about 
PD [12,18]. 
Other psychological factors have been identiﬁ   ed as important 
variables in QoL models. Personality traits, mostly high levels of neuroticism 
and low levels of extraversion, contributed to a worse perception of 
QoL in several diseases [19-26]. The construct of the Type D personality 
was primarily designed for measuring personality traits in coronary 
heart disease patients associated with an increased risk of depressive 
symptoms, a higher number of reinfarctions and higher mortality rates 
[27,28]. In further studies, its validity among non-cardiovascular diseases 
was also shown. Type D was associated with poor physical and mental 
health status among patients with melanoma, Parkinson’s disease, mild 
traumatic brain injury, vertigo complaints, tinnitus or sleep apnoe [29-
31]. The DS-14 questionnaire, which measures Type D, was evaluated as a 
valid instrument for assessing and comparing Type-D personality across 
clinical groups as well [32].
In a previous study we concluded that Type D personality plays 
an important role in QoL assessment in PD patients. Having a Type 
D personality was, after disease severity, the second most important 
determinant of overall QoL and was related to the patient’s worse score in 
the dimensions associated with mental status, as measured by Parkinson’s 
Disease Questionnaire (PDQ-39) [30].
Neurologists should be aware of factors associated with a patient’s 
QoL in order to be able to choose the most effective interventions in the 
framework of treatment. For this study, Type D personality, anxiety and 
depression were assumed to be the variables associated with the perception 
of health status and thus might lead to a worse perception of QoL among 
patients with Parkinson’s disease and patients with multiple sclerosis. The 
aim of this study is to explore whether Type D was associated with the 
mental and physical health status of quality of life in PD and MS patients 
even when depression and anxiety are added to the model.    
Methods
Participants and sample size
Patients with PD and MS in this cross-sectional study were recruited 
from the databases of 4 hospitals and 17 outpatient neurologists and also 
from MS society in the eastern part of the Slovakia between February 
2004 and February 2006. Neurologists from the above mentioned 
institutions diagnosed all patients included in the sample as suffering 
from PD according to the United Kingdom Parkinson’s Disease Society 86 CHAPTER  6
Brain Clinical Criteria [33]. MS patients were diagnosed by neurologists 
according to the diagnostic criteria for MS [4]. Data collection of MS 
patients took place between December 2003 and July 2006. 
Exclusion criteria for both diseases were deﬁ   ned as follows: a) 
patients with a Mini-Mental State Examination (MMSE) score [34] below 
23 points, b) co-morbidities and movement disabilities not caused by MS 
or PD.
Sociodemographic data were derived from questionnaires ﬁ  lled in by 
the patients themselves, and data about neurological treatment from their 
medical records. Disability in each patient was assessed by a neurologist. 
The study was conducted after informed consent was obtained from the 
patients prior to the interview. Participation in the research was voluntary. 
The local Ethics Committee of the University Hospital in Kosice approved 
the study in Kosice on 17 December 2002.
Measures
Disease severity
Disease severity was measured using the Uniﬁ  ed Parkinson’s Disease 
Rating Scale (UPDRS) in PD patients and the Kurtzke Expanded Disability 
Status Scale (EDSS) in MS patients. The UPDRS and EDSS remain the most 
frequently used scoring systems in PD and MS neurological practice.
The UPDRS consists of four parts, pertaining to: mentation and 
mood (Part 1), activities of daily living (Part 2), motor function (Part 3) 
and complications of dopaminergic therapy (Part 4), including motor 
ﬂ  uctuations and dyskinesias. Parts 1, 2, and 4 are interview-based; Part 
3 is based on a clinical examination by a health care professional and 
represents the patient’s condition at the time of the examination. A 
neurologist can score patients from 0 to 176, where higher scores indicate 
increased disease severity [35].
The EDSS is based on testing functional systems: pyramidal, 
cerebellar, brainstem, sensory, bowel and bladder, visual, mental and 
“other“. Disability caused by SM is graded on a continuum from 0 (normal 
neurological examination) to 10 (death caused by MS) [36].  
Type D personality
For assessing Type D personality the DS-14 was used with its constituent 
subscales, negative affectivity (NA) and social inhibition (SI) [28]. 
NA means the tendency to experience negative emotions, like anger, 
dysphoria, irritability, hostile feelings, depressed affect and anxiety. SI is 
the tendency to inhibit these emotions in social interactions [28]. Subjects 
rated these aspects of their personality on a 5-point Likert scale ranging 
from 0=false to 4=true. The NA and SI scales were scored as continuous 87
variables (range 0-28). A cut-off of 10 on both scales (NA ≥ 10 and SI ≥ 
10) was used to classify subjects as Type D [28]. Cronbach’s alpha in the 
original study was 0.88 for NA and 0.86 for SI. In the current study, DS-14 
had good internal consistency in both diseases: Cronbach’s alpha in PD 
patients was .77 for NA and .76 for SI, and for MS patients it was .84 for 
NA and .83 for SI.
HADS
The fourteen-item Hospital Anxiety and Depression Scale (HADS) was 
used for assessing anxiety and depression in non-psychiatric hospital 
departments [37]. Seven items are related to the depression and 7 
to anxiety. Patients responded on a 4-point scale (from 0=absent to 
3=deﬁ  nitely present/severe). Scores ranged from 0 to 21 for each scale, 
where a higher score implied more depression or anxiety. Cronbach’s 
alpha for depression was .79 for both MS and PD patients, and for anxiety 
it was .81 for MS and .69 for PD patients. 
SF-36
The thirty-six item Short Form Health Survey (SF-36) was designed to 
measure health-related quality of life (HRQOL) from the patient’s point 
of view as part of the Medical Outcome Study (MOS). It assesses 8 health 
concepts: a) physical functioning; b) role limitations because of physical 
health problems; c) bodily pain; d) general health perception; e) vitality 
(energy/fatigue); f) social functioning; g) role limitations because of 
emotional problems; and h) general mental health [38]. These scales are 
further combined into 2 scales: a physical component summary score PCS 
(subscales a-d), which contains information about physical heath status 
(PHS), and a mental component summary score (MCS) (subscales e-h), 
which informs about mental health status (MHS). All item scores are 
transformed into a scale from 0 (poor health) to 100 (optimal health) [39]. 
Cronbach’s alphas for the summary scores were .87 for PCS and .78 for 
MCS in PD patients, and .89 for PCS and .89 MCS for patients with MS.
Statistical analyses
Independent sample t-tests were conducted to assess differences between 
the sample of MS and PD patients in age, disease duration, anxiety, 
depression, PCS and MCS. Also the difference of proportions test (CIA) 
was used for assessing gender differences in partnership, Type D and 
education [40]. Next, linear regression analyses were used for assessing 
the contribution of the independent variables in 3 models. The ﬁ  rst model 
included disease severity, gender, age, education and disease duration. 
In the second model Type D personality was added. The third model 88 CHAPTER  6
contained also the variables anxiety and depression. 
Data were analyzed using the software Statistical Package for the 
Social Sciences (SPSS 16.0).
Results
Descriptive statistics
Out of 512 invited patients with Parkinson’s disease, 160 patients agreed 
to participate and ﬁ   lled in the questionnaires, but 7 patients were 
excluded after the personal interview because of the exclusion criteria. 
The ﬁ  nal sample thus consisted of 153 patients (response rate 31.3%). Non-
respondents were on average older compared to the analyzed group in 
age (mean difference 1.69 yrs., SE=.87; t=-1.95; 95% CI .010 – -3.39) and 
there were signiﬁ  cantly more women than men among non-respondents 
(difference -0.0110; SE=.041; 95% CI -.091 – .069).
From 412 MS patients who were asked to participate in the study, 207 
patients were interviewed (52%), and 205 patients did not respond. There 
were no statistically signiﬁ  cant differences between non-respondents and 
participants regarding gender, disease duration and clinical course of MS. 
However, the non-respondents were on average older than the participants 
(mean difference 1.69 yrs., SE=.87; t=-1.95; 95% CI .010 – -3.39).
Eleven patients with PD and nine patients with MS were removed 
from the sample because of missing data. The study ultimately involved 
142 PD patients (73% males; mean age 67.6±9.2 years) and 198 patients 
with MS (32.3% males; 38.4±10.8). The majority of MS patients belonged 
to the relapsing-remitting clinical course (RR-MS; 70.2%). 
All PD patients used antiparkinsonian therapy according 
international guidelines [41,42]. Fifty-six per cent of MS patients in this 
study were being treated with Interferon beta therapy.
Disease severity, Personality, Depression and Anxiety and Quality of Life 
Three models were constructed to explore the contribution to the variance 
of PCS and MCS. 
In Model 1, which consisted of disease severity, gender, age, 
education, and disease duration, worse disease severity was associated 
with a worse score in mental and in physical health status in PD patients, 
and female gender was associated with a worse PCS, as well. Older age 
and more serious disease severity were the main predictors of MCS and 
PCS in MS patients (Table 6.2). 89
Table 6.1 Characteristics of the sample – means and standard deviations (SD) or N (%) on demographic 
and study variables
Parkinson’s 
disease
Multiple 
sclerosis
p / 95% CI
Number of subjects (%) 142 (41.8) 198 (58.2)
Gender
Males (%) 73 (51.4) 64 (32.3) .09; .29 α
Females (%) 69 (48.6) 134 (67.7) -.29; -.09 α
Mean age in years (SD) 67.6 (9.2) 38.4 (10.8) p≤0.001#
Married or living with a partner (%) 96 (67.6) 121 (61.1) -.03; .17 ns α
Education 
elementary (%) 47 (33.1) 11 (5.6) .19; .36 α 
secondary (%) 79 (55.6) 152 (76.8) -.31; -.11 α
university (%) 16 (11.3) 35 (17.7) -.14; .01 ns α
Disease duration (SD) 7.6 (5.9) 2.6 (0.8) p≤0.001#
UPDRS (SD) 36.9 (20.2) - -
EDSS (SD) - 3.0 (1.5) -
Clinical course of MS
relapsing-remitting (%) - 139 (70.2) -
secondary progressive (%) - 27 (13.6) -
primary progressive (%) - 29 (14.6) -
Personality
Negative affectivity (SD) 13.2 (6.3) 12.1 (6.3) ns#
Social inhibition (SD) 13.5 (6.2) 12.0 (6.3) p≤0.05#
Type D (%) 75 (52.8) 89 (44.5) -.03; .18 ns α
Depression (SD) 6.6 (3.6) 4.4 (3.5) p≤0.001#
Anxiety (SD) 8.2 (3.9) 7.2 (4.2) p≤0.05#
Physical component summary (SD) 37.6 (22.0) 48.5 (20.4) p≤0.001#
Mental component summary (SD) 50.9 (17.4) 56.5 (15.7) p≤0.01#
Abbreviations: SD – standard deviation, ns - not significant. # t-tests; α difference of proportion test
When Type D was added (Model 2), the strength of the model 
increased for MCS and PCS in both diseases. In PD patients, Type D was 
signiﬁ  cantly associated with MCS only. However, Type D was signiﬁ  cantly 
associated with the MCS and PCS of QoL for MS patients. Except disease 
severity, which remained signiﬁ  cantly associated with both domains in 
both diseases, age was the second most important variable in the model 
of PCS and MCS in MS patients only (Table 6.2).
Model 3 showed a further increase in explained variance for both 
diseases when the variables anxiety and depression were added (Model 
3). Anxiety and depression were strongly associated with lower scores in 
both subscales of the SF-36 in both groups of patients. Disease severity 
remained signiﬁ  cantly associated with both domains in both diseases. 
Type D personality, female gender and longer disease duration were 
associated with PCS in PD patients (p≤.05). In MS patients higher age 
remained signiﬁ  cantly associated with PCS (Table 6.2).   90 CHAPTER  6
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Discussion
Our ﬁ   ndings demonstrate a signiﬁ   cant association between Type D 
personality and the mental health status of both PD patients and MS 
patients. Type D personality was associated with both dimensions of QoL 
– PCS and MCS. However, this association disappeared in both dimensions 
in MS and in the mental dimension in PD when the variables anxiety 
and depression were added to the model. Higher scores in anxiety and 
depression were strongly associated with QoL in both diseases. We might 
suppose that the actual mood status inﬂ  uences a patient’s perception of 
QoL signiﬁ  cantly more than personality traits, which over time are mostly 
seen as relatively stable. Actual feelings of sadness and fear are related, 
with MS and PD patients both reporting worse QoL. Similar results were 
found in inﬂ  ammatory bowel disease patients, where regression analysis 
showed that disease activity and psychological distress were the strongest 
predictors of QoL impairment, and that personality traits did not play a 
signiﬁ  cant role in QoL [43].
As depression is a clinical symptom for both diseases MS and PD, 
we included all patients into the analyses although the HADS-score could 
be multifactorially determined, e.g. by other organic changes in the brain 
or by psychological reasons associated with factors of non-parkinsonian 
character. To better understand this effect of the origin of the HADS, we 
repeated the analysis after exclusion of clinically depressed and anxious 
patients from the sample and in those patients only. We found that in the 
non-A/non-D sample not only the association between personality traits, 
anxiety, depression and MCS and PCS disappeared except for depression 
and MCS in MS, but also in both diseases the association between UDPRS/
EDSS and MCS disappeared in the full model. In the clinically depressed 
and anxious sample the association between UDPRS/EDSS and MCS and 
PCS is only statistically signiﬁ  cant in PD and not in MS. A statistically 
signiﬁ  cant association between anxiety and MCS is found in PD, not in 
MS, but with PCS only in MS and not in PD. Depression is signiﬁ  cantly 
associated with MCS in both diseases, not with PCS. These ﬁ  ndings need 
further exploration. Nevertheless, having a chronic disease combined 
with depression is a severe disabling combination [44]. 
The predictive value of Type D disappeared in Model 3, although 
there is no doubt that its importance on QoL exists. In a previous study, 
the association between Type D, its subscales and QoL was explored in 
patients with PD [30] and other studies have reported similar results 
[29,31]. Thus, an important question is how personality ﬁ  ts into the ﬁ  nal 
model consisting, besides personality, also of mood variables determining 
QoL in chronically ill patients. A possible answer might be that personality 
traits are associated indirectly with QoL via another variable. Mood 
variables mediating the relationship from personality to QoL was recently 92 CHAPTER  6
suggested by Bartels et al. (2010) in the ﬁ  eld of tinnitus. The authors in that 
study presented a model in which Type D personality on QoL is mediated 
by anxiety and depression in patients with tinnitus [31]. A similar model 
could be assumed for other diseases, as PD or MS.
Also coping style has been proposed as an important mediating 
factor with regard to adaptation to illness [17, 45-47]. Patients who more 
frequently used the emotional coping style reported being more disabled 
by their disease and suffering from poorer mental health and quality of 
life [48-50]. A higher level of neuroticism and a low level of extroversion 
were found to be related to the emotion-focused coping strategy of MS 
patients [51]. Also, in a sample of young adults suffering from headache, 
those reporting lower levels of active pain-coping showed the highest level 
of depressive symptoms [47]. Wahl et al. emphasized that being informed 
about coping strategies and their relationship to aspects of quality of life 
in patients with chronic diseases is important in order to establish health 
care interventions aimed to enhance coping skills [48].
Strengths and limitations
The study‘s main strength is its comparison of both chronic 
neurological diseases from, to our knowledge, a new point of view. The 
results of this study could be helpful for understanding the complexity 
of QoL and its factors in patients with chronic progressive neurological 
diseases. One of the limitations of the study is its cross-sectional design, 
which does not provide us with information about changes to the 
patient over time, and thus does not enable us to compare pathways. 
The low response rate might also have an impact on generalization of 
the results to the total population of PD and MS patients. Regrettably, 
we have no information about the disease duration and disease severity 
of non-respondents. However, it might be supposed that they refused to 
participate in the study because of serious motor complications found in 
the higher stages of PD and MS and due to the need for help from their 
social surroundings.
Implications
Identiﬁ  cation of the mechanisms and consequences of functioning health 
perception in chronically ill patients is still a big challenge for further 
research. Research on QoL in patients with MS and PD should in further 
studies incorporate personality as an integral part of the explanatory 
models of quality of life; next, the relationship between mood status or 
psychological distress, personality traits and QoL should be explored, as 
well as other psychological factors which could contribute to clarify the 
pathways of the variables predicting quality of life of patients with chronic 
diseases [52]. For neurological practice the study outcomes suggest that 
good treatment of mood disorders could substantially contribute to a 
better quality of life. 93
Conclusion
Our ﬁ  ndings show that actual mood status of MS and PD patients could 
be more important than their personality traits in assessment of QoL. To 
complete the model and to clarify the pathway predicting QoL, which 
could explain most of the variance of QoL in chronically ill patients, is 
a great challenge for further research. A similar model could have great 
meaning for clinicians, enabling them to modify their treatment style such 
that each patient can beneﬁ  t optimally from it.
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Chapter 7
General discussion and implications for 
practice and future research
The majority of clinical studies, focusing on quality of life of patients 
with Parkinson’s disease, are oriented on the effect of medical treatment 
of motor and non-motor symptoms in terms of quality of life. Less 
frequently psychological factors are studied which may contribute to 
patients’ perception of their quality of life. Although personal factors 
are part of the International Classiﬁ   cation of Functioning, Disability 
and Health (ICF) model such factors, and among them personality, do 
not belong to the main factors which are taking into account in research 
in chronic diseases. This thesis explores the association of psychological 
factors with the perception of quality of life in patients with PD and, in 
addition, investigates whether psychological factors are associated with 
patient’s help-seeking behavior and contribute to quality of life. 
In this chapter ﬁ   rstly the main ﬁ   ndings will be presented and 
discussed. Secondly, the study strengths and limitations of the research 
are mentioned. Last part is focusing on the implications of the results 
for practice, for the patients with Parkinson’s disease and for further 
research. 
7.1  Main findings
The main ﬁ   ndings were organized according the main research 
questions. 
7.1.1   The exploration of the associations between various personality traits, 
neuroticism, extroversion, negative affectivity, social inhibition and 
Type D personality and quality of life in PD patients. In addition, gender 
differences were examined as well.
We expected an association between personality traits (neuroticism, 
extroversion, negative affectivity, social inhibition and Type D personality) 
and quality of life in patients with Parkinson’s disease. We also 
hypothesized, that each of the domains of quality of life is determined by 
different predictors. For this reason we used the PDQ-39 and its 8 scales: 
mobility, activities of daily living, emotional well-being, stigma, social support, 
cognition, communication and bodily discomfort. 98 CHAPTER  7
Into the models variables were added, which may inﬂ  uence the 
association between personality traits and quality of life: disease severity 
(measured by UPDRS), disease duration and age. Despite their strong 
inﬂ  uence, the personality traits explained 8-24% of the variance of 6 
dimensions of QoL (Chapter 2 and Chapter 3, Table 2.3, Table 3.3). After 
the UPDRS, Type D explained most of the variance in the overall model 
of quality of life for patients with Parkinson’s disease and it was strongly 
associated with the dimensions emotional well-being, stigma, social support, 
cognitions and communication, but it was not signiﬁ  cantly associated with 
mobility, activities of daily living and bodily discomfort, which were explained 
only by the UPDRS. Patients with higher scores on the neuroticism scale 
from the Eysenck Personality Questionnaire reported similarly like Type 
D patients a signiﬁ  cantly worse status in the domains of emotional well-
being, stigma, social support and also, on the contrary to Type D, in bodily 
discomfort, but not in mobility, activities of daily living and cognitions.
In comparisons between genders differences were found. Type D 
explained emotional well-being in both genders. Among men, Type D was 
an important factor in the models of stigmatization by illness, cognition and 
communication but personality played no role in these models among 
women. In both genders, negative affectivity (NA) and neuroticism 
explained 8.5-13.4 % of the variance in emotional well-being. A higher score 
in NA was associated with a worse score in the dimensions of stigma and 
cognition in men, while in women it was associated with a worse score in 
social support. In the model of overall quality of life, NA appeared to be 
important for both genders, contrary to social inhibition, which did not 
play a role in the model. Neuroticism played a role in the subscales of 
stigma and social support in women, but it did not appear to be important 
in men. 
7.1.2   Differences between delayers and non-delayers regarding psychological 
factors associated with quality of life in patients with PD were explored 
and additionally the impact of fear and anxiety on help-seeking behavior 
in non-parkinsonian diseases.
Psychological factors might play a role in delaying patients and could 
affect QoL of such patients. The length of the patient’s delay might give 
important information for the clinician. Because of the lack of such papers 
in neurological journals, we decided to do a review on delay in the ﬁ  eld 
of cancer, a frequently slow developing disease, and acute myocardial 
infarction, an acute developing disease.
  The intensity of fear is a factor, which has an impact on the 
decision making process of the patient. The higher the level of fear the 
shorter the time of the arrival to the medical doctor was. ‘Being worried’ 99
was not enough for seeking help, but probably it is starting the process of 
internal thinking about the possibility of being treated. ‘Fear’ seems to be 
a factor for longer delay, but the decision process in patients experiencing 
fear was also inﬂ  uenced by other factors, such as embarrassment, pressure 
from a patient’s relatives or fear of ﬁ  nancial consequences. ‘Being anxious’ 
and feelings of ‘panic’ or ‘death anxiety’ was associated with seeking help 
within a few hours.
Shortening of the patient’s delay has in case of cancer and AMI 
impact on successfulness of treating and, indirectly, on their quality of 
life. The aim of our study was to explore, whether patients with PD are 
different in their quality of life stratiﬁ  ed for patient’s delay and whether 
the association of personality traits and quality of life in patients with PD 
is inﬂ  uenced by delay.  Patients with PD who came earlier to see a health 
care professional differed from delayers by a worse functional status and 
they had a signiﬁ  cantly lower physical quality of life than delayers. In 
neuroticism no differences were found, for both groups neuroticism was 
strongly associated with lower quality of life – mental and also physical. 
However, non-delayers were more extrovertly oriented than delayers. 
7.1.3   The comparison of the role of the association of psychological factors 
– Type D personality, anxiety and depression – with quality of life in 
patients with PD and multiple sclerosis (MS).
Mood disorders, especially depression, are among the clinical symptoms 
of both diseases [1,2]. Because in previous studies we concluded, that 
personality traits (especially Type D and neuroticism) are determinants of 
quality of life in patients with Parkinson’s disease, we explored whether 
Type D was associated with quality of life in PD and MS patients even 
when depression and anxiety was added to the model of patients’ self-
perceived quality of life. 
Type D personality signiﬁ   cantly associated with worse mental 
health status of PD patients and with decreasing scores in mental and 
physical domains of quality of life in MS patients. However, when the 
actual mood factors depression and anxiety were added, the signiﬁ  cant 
association of personality traits with quality of life disappeared. This 
ﬁ  nding, the disappearing signiﬁ  cance between personality and QoL after 
adding mood variables, suggests a combined pathway from personality 
via mood variables to quality of life.100 CHAPTER  7
7.2 Discussion of the main findings
Personality traits and quality of life 
Findings from longitudinal studies show that Parkinson’s disease affects 
patients’ lives in a broader sense than by physical impairment, and that 
despite modern treatment, the impact of the disease increases as the 
disease progresses [3]. Personality, according the ICF model, belongs to 
the contextual factors, which inﬂ  uence patient’s functioning and disability 
[4]. Furthermore, a review indicated that psychological and social 
variables inﬂ  uence perception of health status, mostly in case of pain, 
more powerfully than biological factors [5]. Several studies conﬁ  rmed that 
personality affects patients’ reports of symptoms of disease; especially 
neuroticism and extraversion were associated with the tendency to recall 
physical symptoms as being worse than they really were [6,7]. In addition, 
extraversion inﬂ  uences the level of coping with chronic disease, which 
inﬂ  uences, negatively or positively, the level of quality of life [8,9]. In 
this thesis it was shown, that in case of patients with Parkinson’s disease, 
personality traits (directly, and also indirectly through the actual mood) 
play an important role in quality of life assessment, as well. In line with 
our results, we can state, that quality of life in patients with Parkinson’s 
disease can be partially explained by personality traits.
In other studies gender differences were observed in patients 
with Parkinson’s disease. Mildly signiﬁ   cant differences in disability 
and quality of life have been noted between genders in parkinsonian 
patients: women reported more disability and reduction of quality of life 
than men [10]. Findings of Huang (2007) showed that women reported 
more problems in stigmatization, and men reported more problems in 
activities of daily life. The author also observed, that women with higher 
levels  of facial expressivity felt less problems in social support and 
communication then women with less facial expressiveness due to the 
Parkinson mask [11]. Worse score in social support in women in our study 
was explained by negative affectivity, but it could be also associated with 
their worse communicational ability associated with the decreased facial 
expressiveness as showed by Huang’s study [11]. The aim for further 
studies is to compare these results with studies in gender differences of 
other diseases for better understanding of the impact of psychological 
factors like personality on patients’ complaints. 
Delayers and non-delayers and quality of life
Even though Parkinson’s disease has no such fatal consequences 
for surviving or successfulness of treatment as other diseases, e.g. 
acute myocardial infarction or cancer, patient’s delay is an interesting 
phenomenon in this case. Outpatient neurologists report differences 101
in assessment of impairment by PD patients themselves, which may 
caused early or late help-seeking – patients with serious impairment 
sometimes do not seek help so early, as it would be expected. According 
to our ﬁ  ndings delayers and non-delayers among PD patients differed, 
except disease severity, but also regarding extraversion (Chapter 5). 
Extraversion positively correlates with social activity and social support 
[12,13]. Therefore, patients with health complaints with a supporting 
environment tend to seek help sooner. The possibility of sharing feelings 
with somebody has a signiﬁ  cant impact on the decision to consult a 
specialist [14-16]. Late help seeking could be associated with three main 
reasons: a) a low disease severity; b) introversion and/or lack of social 
contacts; c) fear from consequences of the visit medical care, leading to 
delay. Prevention of patient’s delay in PD patients should be based on 
providing information how to recognize symptoms of disease and also 
about treatment and rehabilitation. This may lead to minimize fear from 
the unknown for the people involved, and for other people from society it 
can help to act and help to people from their surrounding.  
Personality, mood disorders and quality of life 
In accordance with results presented in Chapter 6 we can suppose that 
actual mood disorders, depression and anxiety, have more serious impact 
on quality of life than personality traits not only in PD patients, but also in 
patients with multiple sclerosis. However, predispositions to depression 
and anxiety are closely associated with neuroticism and extraversion. 
As results of several study shows, high extraversion scores may protect 
against depression and neuroticism reﬂ   ects symptoms of depression 
[17-19]. Therefore, for further research in factors of quality of life can be 
hypothesized, that mood disorder may mediate the relationship between 
personality traits and quality of life. Mood variables mediating the 
relationship from personality to QoL was recently suggested by Bartels 
and colleagues in the ﬁ  eld of tinnitus. The authors in that study presented 
a model in which Type D personality on quality of life is mediated by 
anxiety and depression in patients with tinnitus [20]. A similar model 
could be assumed for Parkinson’s disease, as well.
7.3 Study strengths and limitations
The thesis is focused on psychological factors relevant for Parkinson’s 
disease, a topic which is not included into most clinical studies. These 
factors contribute to a comprehensive picture of the total disease impact 
on patients’ quality of life. Main strength of the thesis is the use of 
psychological factors as independent variables associated with quality of 
life in patients with Parkinson’s disease. Most studies about quality of 102 CHAPTER  7
life in those patients are focusing on the association of clinical symptoms 
and their inﬂ  uence on patient’s overall quality of life or on the effect of 
the treatment process. Studies explaining the impact of psychological 
factors on perception of quality of life in this group of patients, except 
mood disorders, are missing. The results of our thesis could be helpful for 
understanding the complexity of quality of life and its factors in patients 
with Parkinsonism. Although the association between patients’ delay 
and personality traits was still not been adequately explained, we try to 
contribute to the knowledge about this interesting phenomenon.
The low response rate was a limitation of this study. It may have an 
impact on generalization of the results to the total population of PD patients. 
Non-respondents were older than respondents, so it may be hypothesized 
that they refused to participate in the study because of serious motor 
complications found in the higher stages of PD and due to the need for 
help from their social surroundings. Regrettably, we have no information 
about disease duration and disease severity of non-respondents. Another 
limitation was the cross-sectional design of the study, not enabling us to 
explore causal relationships between variables. However, we would like 
also to point out, that the tendencies in the majority of the present studies 
are focused on the objectiﬁ  cation of the patient’s perception of quality of 
life and furthermore on studying factors, which could explain totally the 
model of quality of patient’s life. However, these study approaches are 
not centered to the patient and his quality of life. Quality of life starts 
to be an abstract concept, which is related to answers of the sample of 
the patients with a certain diagnosis and which disease is measured by 
objective and valid instruments. Duchan warns against the danger of 
this kind of studies - our own study belongs to this type - because they 
could lead to ignore patient’s experience as something unscientiﬁ  c and 
too subjective [21]. As was pointed out, without adequate preliminary 
qualitative research, quantitative research might risk a misanalysis of the 
target phenomenon, at the very least by the omission of relevant factors 
and inclusion of irrelevant ones [22]. 
7.4 Implications of the findings
Implications for practice 
More knowledge about the association of personality traits and their 
contribution on patients’ quality of life may give a clearer view on how 
to evaluate patient complaints in the case of worsening quality of life, 
especially in patients with Parkinson’s disease. Assessment of quality of 
life of patients is not easy for clinicians especially because of blank stare 
and low mimic (“Parkinson’s mask”) which complicate communication 103
and decrease the validity of information about the well-being or the health 
status from the patient. Health-care providers should be aware of the 
potential relationship between facial expressiveness and the relationship 
with the patient, which brings implications for family, community, and 
therapeutic relationships [11]. Neurologists should be aware of factors 
associated with patient’s quality of life in order to be able to choose the 
most effective interventions in the framework of treatment. 
The gender aspect of quality of life appears to be an important topic, 
contributing to the knowledge about psychological differences between 
men and women. Consequently, coping styles and self-management skills 
in both genders might also differ, as has been shown in several studies 
on cancer and chronic pain [23,24]. For adjustment to the chronic pain 
problems the aforementioned coping styles were more important in 
women, whereas possessing a trusting relationship was more important 
for men in their adjustment process [22]. In cancer patients men are 
focusing on the positive sides more often than women did (P<0.01) 
[25]. Women, during stressful times, prefer to talk about it and share 
their feelings with others, but men with cancer would rather not [26]. 
Differences between men and women could be determined by cultural 
roles [26,27]. Different needs of men and women with PD should be taken 
into account in psychological intervention programs, which need to be 
different for both genders.
  Quality of life of PD patients is closely associated with their 
functional status and reducing their activities of daily living, losing ability 
to devote to their hobbies and, consequently, reducing their participation 
in social life. Their social surrounding taking care on them and it could 
evoke feeling of guilt and dependence. Early help-seeking could prolong 
their active life and improve quality of life, especially in patients with 
diseases, which affect motor abilities, e.g. Parkinson’s disease. 
Recommendations for future research
One of the limitations of the study was the low response rate. Patients, 
even they were contacted via phone, had several problems to participate 
in the study. The possibility of visiting patients at home could increase 
their willingness to agree with participation. 
For quantitative studies the ICF model helps the researcher to include 
all important factors to the research project and it helps to understand 
the concept of quality of life in a broader context. Well-designed gender 
studies are of importance for a profound understanding of the impact of 
gender on the perception of quality of life and it can improve medical care. 
The need to differentiate between women and men is observed also in 
other diseases than PD, e.g. in oncological patients [28]. Gender inﬂ  uences 104 CHAPTER  7
social roles of patients with Parkinson’s disease, thus it can moderate the 
patient’s perceptions of quality of life [11]. Further studies are needed 
to explore the health and psychosocial consequences of the gender 
difference in self-rated social status – models of quality of life for men 
and women could be composed from different variables. The important 
question is whether gender differences are disease speciﬁ  c or that they 
are a constant phenomenon also present in other diseases. Therefore, 
psychological factors should be an important part of the diagnostic and 
treatment process of patients with Parkinson’s disease, because the report 
of the patient about his/her symptoms may be distorted by his actual 
psychological status or personality and more studies based on qualitative 
analyses are needed. Qualitative studies could help us to interprete 
quantitative ﬁ  ndings and they might help to understand the meanings, 
practices and context of measured variables. 
Conclusion
Because of the increasing mean age of European population, it is more 
and more important to provide care for patients in a higher age. With 
increasing age a decreasing quality of life is associated not only because 
of the increasing occurrence of various diseases, which limit patients in 
his/her activities of daily living, but also because of factors associated 
with social conditions and psychological factors. Knowledge about 
factors associated with decreasing (but also increasing) quality of life in 
aged people means a challenge for future research and personality traits 
should be one of important variables of the models. Developing effective 
disease-management programs for patients with chronic diseases such 
as Parkinson’s disease incorporating all possible knowledge about 
inﬂ  uencing factors is needed.
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Summary
Nowadays, approximately 6 million people are affected by Parkinson’s 
disease (PD) worldwide, but this number is not exact, because many 
people remain undiagnosed. The motor impairment, which is the most 
visible symptom of the disease, affects all domains of the patient’s life 
– physical, psychological and social. A slow and uncertain movement, 
tremors and falls inhibit patients to do activities of daily living, to fully 
use the leisure time, and to be active in social life. Although there are 
many studies, which are focused on measurement the quality of life (QoL) 
of those patients, studies about their personality and other psychological 
factors associated with QoL in PD patients are scarce. In our research 
we focused mostly on personality (extraversion, neuroticism, type D 
personality, negative affectivity and social inhibition) and mood disorders 
(depression, anxiety) as factors associated directly with QoL or indirectly 
– through patient’s delay (Figure 1.3).
The ﬁ  rst aim of Chapter 2 was to explore whether neuroticism and 
extraversion contribute to the variance in QoL in patients with Parkinson’s 
disease. Multiple linear regression analyses were performed to identify 
how much the variance of the dependent variables, dimensions of the 
questionnaire PDQ-39 (mobility,  activities of daily living,  emotional well-
being, stigma, social support, cognition, communication and bodily discomfort), 
could be explained by the personality traits if controlled for the relevant 
sociodemographic (age and gender) and clinical variables (disease 
severity and disease duration). After disease severity, which we expected 
as the most important factor inﬂ  uencing QoL, neuroticism was the second 
most important variable in the model of QoL, particularly in domains 
associated with psychological processes: emotional well-being, social support, 
stigma and bodily discomfort, explaining 5-24% of the variance of QoL. The 
second aim of the study was to explore gender differences in the variables 
in the models of QoL. A higher score in extraversion was signiﬁ  cantly 
associated with better emotional well-being in males, but surprisingly, with 
worse emotional well-being in females. According results we can hypothesize, 
that neuroticism is affecting the perception of QoL and in further research 
gender differences - males and females develop different ways of coping 
and experiencing the world - can be taken into account.
In the Chapter 3 we continued in line with results presented 
in  Chapter 2. The aim of this study was to evaluate whether Type D 
personality, and its two subscales – negative affectivity (NA) and social 
inhibition (SI), predicts QoL in patients with PD and, in addition, gender 
differences in Type D personalities were explored. Type D was negatively 108 SUMMARY
associated with overall QoL in PD patients and with all dimensions except 
mobility, activities of daily living and bodily discomfort. In women, a higher NA 
explained the higher dissatisfaction with social support. For overall QoL, 
NA explained 13.2% (P<0.001) of the variance in males and 9.3% (P<0.01) 
of the variance in females. SI also explained a maximum of 5.5% (P<0.05) 
of the variance in communication in men and 7.3% (P<0.05) stigma in women. 
In short, personality traits play an important role in the explanation of 
QoL in PD patients. The gender differences suggest that models of QoL 
for men and women are composed from different variables.
Chapter 4 presents a systematic review focusing on the role of the 
intensity of fear in patient’s delay in seeking medical help. We used 
studies about rather common diseases - cancer and myocardial infarction, 
mostly for the reason of quantity of such kind of studies in those diseases.   
In a search of literature published between 1990 and June 2009, 161 articles 
were found. After the use of inclusion and exclusion criteria, 11 articles in 
cancer and 4 articles in myocardial infarction remained. Fear ranged on 
a scale from the lowest level of ‘being worried’, which is not enough to 
initiate the early contacting of a specialist, to the level of ‘panic’. People 
who were extremely alarmed about the ﬁ  rst signs of their disease were 
ready to consult their general practitioner (GP) within a few hours. The 
main result of this review was to show, that the level of fear inﬂ  uenced 
decision-making. This important factor should be taken into account 
when facilitating help-seeking by patients, and especially in cases of low 
level of fear, encouraging them to seek medical care.
Patient’s delay was also the topic of Chapter 5. Here we explored 
whether QoL in PD patients who delayed in seeking help was associated 
with personality traits. Because of the intermittent occurrence and slow 
progress of symptoms in the ﬁ  rst phase of the disease, in several cases 
patients who sought medical help within 1 year of the appearance of the 
ﬁ  rst signs and symptoms of the disease were marked as ‘non-delayers’ 
and those over 1 year as ‘delayers’. This period was deﬁ  ned on the basis 
of interviews with patients – when the onset of disease was not dramatic, 
people attributed them frequently to ‘stress’. Non-delayers scored 
higher in extroversion, which was associated also with better scores in 
physical and mental health summary score. Results showed, that social 
interactions, associated with an extrovertly oriented personality, can force 
decision making on help-seeking.
Many studies conﬁ  rmed that anxiety and depression were assumed 
to be the variables associated with worsening QoL in various diagnoses. 
Because in previous studies we concluded, that personality traits 
(especially Type D and neuroticism) are determinants of quality of life, in 
Chapter 6 we examined whether Type D is associated with the mental and 
physical health status of quality of life in PD and in patients with multiple 
sclerosis (MS) even when depression and anxiety were added to the model. 109
Our ﬁ  ndings showed that higher scores in anxiety and depression were 
strongly associated with QoL in both diseases. Although initially Type 
D personality was associated with both dimensions of QoL – physical 
and mental health summary score, this association disappeared in both 
dimensions in MS and in the mental dimension in PD when the variables 
anxiety and depression were added to the model. Our ﬁ  ndings suggest 
a combined pathway from personality via mood variables to quality of 
life. 
In Chapter 7 the main ﬁ  ndings were discussed and implications for 
practice and for further research were formulated. In line with our results, 
we can state, that quality of life in patients with Parkinson’s disease can 
be partially explained by personality traits and also the gender aspect 
of quality of life appeared to be an important topic contributing to the 
knowledge about psychological differences between men and women 
with PD. Actual mood disorders, depression and anxiety, are modifying 
the importance of personality traits in QoL and they seem to have more 
serious impact on quality of life than personality traits not only in PD 
patients, but also in patients with multiple sclerosis. According to our 
ﬁ  ndings, delayers and non-delayers among PD patients differed regarding 
extraversion, which positively correlates with social activity and social 
support. Therefore, patients extravertly oriented who have the possibility 
to share feelings with somebody, seek help sooner then patients with low 
score in extraversion.
The limitation of the study was the relatively low response rate, 
which may have an impact on generalization of the results to the total 
population of PD patients. Also using longitudinal data in further research 
could help us better explaining causal relationships between variables. 
Further research of patient’s delay should also combine qualitative and 
quantitative research for more precise interpretation of ﬁ  ndings. Using 
qualitative methods could help to understand the meanings, practices and 
context of measured variables. To choose the most effective interventions 
in the framework of treatment, neurologists should take into account 
their patient’s personality and his actual mood or motivation, next to the 
worsening or improving of the symptoms of the disease.110 SUMMARY111
Samenvatting
Wereldwijd zijn ongeveer 6 miljoen mensen getroffen door de ziekte van 
Parkinson (PD). Echter, dit aantal is niet exact, omdat veel mensen niet 
gediagnosticeerd zijn. De motorische stoornissen, het meest zichtbare 
symptoom van de ziekte, zijn van invloed op alle domeinen van het leven 
van de patiënt - fysiek, psychologisch en sociaal. Langzame en onzekere 
bewegingen, tremoren en valneigingen beperken patiënten om volop deel 
te nemen aan de activiteiten van het dagelijks leven, om ten volle gebruik 
maken van de vrije tijd, en om actief te zijn in het sociale leven. Hoewel 
er veel studies zijn die gericht zijn op de meting van de kwaliteit van 
leven van deze patiënten, zijn studies over hun persoonlijkheid en andere 
psychologische factoren die samenhangen met de kwaliteit van leven van 
PD-patiënten schaars. In ons onderzoek concentreerden we ons vooral 
op de persoonlijkheid (extraversie, neuroticisme, type D persoonlijkheid, 
negatieve affectiviteit en sociale inhibitie) en stemmingsstoornissen 
(depressie, angst) als factoren die direct verband houden met kwaliteit 
van leven van de patiënt of indirect - via uitstel van hulpzoekgedrag van 
de patiënt.
Het eerste doel van Hoofdstuk 2 was te onderzoeken of neuroticisme 
en extraversie bijdragen aan de variantie in kwaliteit van leven bij patiënten 
met de ziekte van Parkinson. Multipele lineaire regressie-analyses werden 
uitgevoerd om te bepalen hoe groot de variantie van de afhankelijke 
variabelen, in casu de dimensies van de vragenlijst PDQ-39 (mobiliteit, 
activiteiten van het dagelijks leven, emotioneel welzijn, stigmatisering, sociale steun, 
cognitie, communicatie en lichamelijk ongemak), kunnen worden verklaard 
door de persoonlijkheidskenmerken gecontroleerd voor de relevante 
sociaal-demograﬁ   sche (leeftijd en geslacht) en klinische variabelen 
(ernst en duur van ziekte). De ernst van de ziekte was zoals verwacht 
de belangrijkste factor geassocieerd met kwaliteit van leven. Daarna was 
neuroticisme de belangrijkste variabele, in het bijzonder in de domeinen 
geassocieerd met psychologische processen: emotioneel welbevinden, 
sociale steun, stigmatisering en lichamelijk ongemak, met een verklaring van 
5-24% van de variantie van kwaliteit van leven. Het tweede doel van het 
onderzoek was om sekseverschillen in de variabelen in de modellen van 
de kwaliteit van leven te verkennen. Een hogere score in extraversie was 
signiﬁ  cant geassocieerd met een beter emotioneel welzijn bij mannen, maar 
verrassend genoeg, met een slechter emotionele welzijn bij vrouwen. Op 
basis van de resultaten mogen we veronderstellen dat neuroticisme van 
invloed is op de perceptie van kwaliteit van leven;  in verder onderzoek 
moet er rekening mee worden gehouden dat sekseverschillen ten 112 SAMENVATTING
grondslag kunnen liggen aan verschillende manieren van omgaan met en 
het ervaren van de wereld.
In  Hoofdstuk 3 zijn we gaan voortbouwen op de resultaten zoals 
gepresenteerd in Hoofdstuk 2. Het doel van deze studie was om te evalueren 
of Type D persoonlijkheid met de twee subschalen - negatieve affectiviteit 
(NA) en sociale inhibitie (SI) - kwaliteit van leven voorspelt bij patiënten met 
PD. Bovendien zijn verschillen in Type D persoonlijkheid tussen mannen 
en vrouwen onderzocht. Type D is negatief geassocieerd met de algemene 
kwaliteit van leven in PD patiënten in alle dimensies, met uitzondering 
van de mobiliteit, activiteiten van het dagelijkse leven en lichamelijke ongemak. Bij 
vrouwen verklaarde een hogere NA de hogere ontevredenheid met sociale 
steun. Van de variantie in de algemene kwaliteit van leven verklaarde NA 
13,2% (P <0,001) bij mannen en 9,3% (P <0,01) bij vrouwen. SI verklaarde 
ook een maximum van 5,5% (P <0,05) van de variantie in de communicatie 
bij mannen en 7,3% (P <0,05) van de stigmatisering bij vrouwen. Kortom, 
persoonlijkheidskenmerken spelen een belangrijke rol bij het verklaren 
van kwaliteit van leven bij PD patiënten. De verschillen tussen mannen en 
vrouwen suggereren dat modellen van kwaliteit van leven voor mannen 
en vrouwen zijn samengesteld uit verschillende variabelen.
In Hoofdstuk 4 wordt een systematische review beschreven die gericht 
is op de rol van de intensiteit van angst bij de patiënt op uitstelgedrag bij 
het zoeken naar medische hulp. We gebruikten onderzoeken over veel 
voorkomende ziekten - kanker en myocardinfarct, overwegend vanwege 
de reden dat dit soort studies bij deze ziekten in zekere mate is verricht. 
In een eerste onderzoek naar de literatuur gepubliceerd tussen 1990 en 
juni 2009 werden 161 artikelen gevonden. Na het gebruik van inclusie- 
en exclusiecriteria, bleven 11 artikelen over kanker en 4 artikelen over 
een myocardinfarct over. Angst varieerde op een schaal van het laagste 
niveau van ‘ongerust zijn’, dat niet voldoende is om een vroeg contact 
op te nemen met een specialist, tot het niveau van ‘paniek’. Mensen die 
zeer verontrust waren over de eerste tekenen van hun ziekte waren bereid 
om hun huisarts  binnen een paar uur te raadplegen. Het belangrijkste 
resultaat van dit onderzoek was aan te tonen dat het niveau van angst 
het uitstelgedrag beïnvloedt. Met deze belangrijke factor moet rekening 
worden gehouden bij het vergemakkelijken van het zoeken naar hulp 
door de patiënten, door vooral de niet erg verontruste patiënten aan te 
moedigen om medische zorg te zoeken.
Uitstelgedrag van patiënten was ook het onderwerp van Hoofdstuk 
5. Hier hebben we onderzocht of kwaliteit van leven bij PD patiënten met 
uitstelgedrag was geassocieerd met persoonlijkheidskenmerken. Vanwege 
het intermitterende voorkomen en de trage progressie van de symptomen 
in de eerste fase van de ziekte zijn patiënten die medische hulp zochten 
binnen 1 jaar na het verschijnen van de eerste tekenen en symptomen van 
de ziekte gedeﬁ  nieerd als ‘niet-delayers’ en degenen waarbij dit langer 113
dan 1 jaar duurde als ‘delayers’. Deze periode is vastgesteld op basis van 
interviews met patiënten. Was het begin van de ziekte was niet dramatisch, 
dan schreven de mensen het vaak toe aan ‘stress’. Niet-delayers scoorden 
hoger in extraversie, dat ook werd geassocieerd met betere scores in de 
samenvattende lichamelijke en geestelijke gezondheid score. De resultaten 
toonden aan dat sociale interacties, samen met een extrovert georiënteerde 
persoonlijkheid, van invloed kan zijn op het besluitvormingsproces met 
betrekking tot het hulpzoekgedrag van de patiënt.
Talrijke studies hebben bevestigd dat angst en depressie variabelen 
zijn die gepaard gaan met verslechtering van de kwaliteit van leven bij 
verschillende ziektebeelden. Omdat in eerdere studies geconcludeerd is, 
dat de persoonlijkheidskenmerken (met name Type D en neuroticisme) 
determinanten van kwaliteit van leven zijn, hebben we in Hoofdstuk 6 
onderzocht of Type D in verband gebracht kan worden met de geestelijke 
en lichamelijke gezondheidstoestand bij PD patiënten en bij patiënten met 
multiple sclerose (MS), zelfs als depressie en angst werden toegevoegd aan 
het model. Onze bevindingen toonden aan dat hogere scores van angst 
en depressie sterk werden geassocieerd met kwaliteit van leven bij beide 
ziektebeelden. Hoewel aanvankelijk Type D persoonlijkheid geassocieerd 
was met beide dimensies van kwaliteit van leven – de samenvattende 
lichamelijke en geestelijke gezondheid score - verdween deze associatie 
bij beide dimensies in MS en in de geestelijke dimensie in PD wanneer de 
variabelen angst en depressie werden toegevoegd aan het model. Onze 
bevindingen suggereren een gecombineerd pad van de persoonlijkheid 
via de stemmingsvariabelen naar kwaliteit van leven.
In Hoofdstuk 7 worden de belangrijkste bevindingen besproken en 
implicaties voor de praktijk en voor verder onderzoek geformuleerd. In 
overeenstemming met onze resultaten, kunnen we stellen, dat de kwaliteit 
van leven bij patiënten met de ziekte van Parkinson gedeeltelijk kan 
worden verklaard door persoonlijkheidskenmerken en ook het ‘gender’-
aspect van de kwaliteit van het leven bleek een belangrijk onderwerp 
dat bijdroeg aan onze kennis over de psychologische verschillen tussen 
mannen en vrouwen met PD. Actuele stemmingsstoornissen, depressie 
en angst, kunnen het verband tussen persoonlijkheidskenmerken en 
kwaliteit van leven modiﬁ  ceren en ze lijken meer ernstige gevolgen voor de 
kwaliteit van leven te hebben dan persoonlijkheidskenmerken, niet alleen 
bij PD-patiënten, maar ook bij patiënten met multiple sclerose. Volgens 
onze bevindingen, verschilden ‘delayers’ en ‘niet-delayers’ bij PD patiënten 
ten aanzien van extraversie, die positief correleert met sociale activiteiten 
en sociale steun. Daarom zullen extrovert georiënteerde patiënten die de 
mogelijkheid hebben om emoties te delen met iemand anders, sneller 
hulp zoeken dan patiënten met een lage score in extraversie.
De beperking van de studie was de relatief lage respons, die een effect 
kan hebben op de generalisatie van de resultaten naar de totale populatie 114 SAMENVATTING
van PD patiënten. Longitudinale gegevens uit verder onderzoek zouden 
ons kunnen helpen meer inzicht te krijgen in de causale verbanden tussen 
de variabelen. Nader onderzoek naar uitstelgedrag van de patiënt zou 
kwalitatief en kwantitatief onderzoek moeten combineren voor een meer 
nauwkeurige interpretatie van de bevindingen. Kwalitatieve methoden 
zouden kunnen bijdragen om de betekenis, handelingen en de context 
van de gemeten variabelen beter te begrijpen. Voor het kiezen van de 
meest effectieve interventies in het kader van de behandeling van PD 
patienten, zouden neurologen meer rekening moeten houden met de 
persoonlijkheidskenmerken van hun patiënt en zijn werkelijke stemming, 
naast de verergering of verbetering van de symptomen van de ziekte.115
Zhrnutie
V súčasnosti trpí približne 6 miliónov ľudí na svete Parkinsonovou 
chorobou (PD). Tento odhad však nemožno považovať za presný, 
pretože nie všetci postihnutí ochorením sú aj diagnostikovaní. Motorické 
poškodenie, ktoré je najviditeľnejším symptómom ochorenia, ovplyvňuje 
všetky oblasti pacientovho života – fyzickú, psychickú aj sociálnu. Pomalý 
a neistý pohyb, tras a pády inhibujú pacienta v aktivitách každodenného 
života, vo voľnočasových aktivitách a v jeho/jej sociálnom živote. Aj keď 
sa mnohé výskumy zameriavajú na kvalitu života tejto skupiny pacientov, 
štúdie z pohľadu ich osobnosti a iných psychologických faktorov, ktoré 
s kvalitou života súvisia, sú stále zriedkavé. V našom výskume sme sa 
zamerali na osobnosť (extroverziu, neuroticizmus, osobnosť typu D, 
negatívnu afektivitu a sociálnu inhibíciu) a na poruchy nálad (depresiu a 
anxietu) ako na faktory súvisiace s kvalitou života priamo alebo nepriamo 
– prostredníctvom oddiaľovania vyhľadania odbornej starostlivosti 
(Schéma 1.3).
Hlavným cieľom Kapitoly 2 bolo zistiť, či sa neuroticizmus a extroverzia 
podieľajú na našom modeli kvality života pacientov s Parkinsonovou 
chorobou. Pomocou viacnásobnej lineárnej regresie sme zisťovali, či miera 
variancie jednotlivých dimenzií dotazníka na meranie kvality života ľudí 
s PD (PDQ-39), konkrétne mobilita, každodenné aktivity, emocionálna pohoda, 
stigma,  sociálna opora,  kognitívne fakory,  komunikácia a telesný diskomfort, 
môže byť vysvetlená pomocou osobnostných vlastností za predpokladu, 
že kontrolujeme model aj z hľadiska relevantných sociodemograﬁ  ckých 
(vek a pohlavie) a klinických premenných (závažnosť ochorenia a dĺžka 
ochorenia). Hneď po faktore závažnosti ochorenia, o ktorom sme 
predpokladali, že bude najdôležitejším faktorom ovplyvňujúcim kvalitu 
života, bol druhou závažnou premennou neuroticizmus, ktorý súvisel 
hlavne s modelmi dimenzií súvisiacich s psychologickými procesmi: 
emocionálna pohoda,  sociálna opora,  stigma a telesný diskomfort, v ktorých 
vysvetľoval 5-24% variancie kvality života. Sekundárnym cieľom výskumu 
bolo zistiť rozdiely v modeloch kvality života medzi pohlaviami. Vyššie 
skóre v extroverzii signiﬁ   kantne súviselo s lepším skóre v dimenzii 
emocionálna pohoda u mužov, ale, prekvapujúco, s horším skóre v tej istej 
dimenzii, emocionálna pohoda, u žien. Na základe týchto výsledkov môžeme 
predpokladať, že neuroticizmus ovplyvňuje vnímanie kvality života. 
Nasledujúci výskum v oblasti rodových rozdielov by mal preto zohľadniť 
odlišné kopingové stratégie mužov a žien a ich rozdielne prežívanie.
Kapitola 3 nadväzuje vo výsledkoch na Kapitolu 2. Cieľom tejto štúdie 
bolo zistiť, či osobnosť typu D a jej dve podškály, negatívna afektivita (NA) 116 ZHRNUTIE
a sociálna inhibícia (SI), predikujú kvalitu života pacientov s PD. Zisťovali 
sme aj rodové rozdiely v osobnostiach typu D vzhľadom na kvalitu 
života. Typ D negatívne asocioval s celkovým skóre kvality života a so 
všetkým dimenziami PDQ-39 okrem mobility, aktivít každodenného života 
a telesného diskomfortu. U žien vyššia NA vysvteľovala vyššiu nespokojnosť 
v dimenzii sociálna opora. V celkovom skóre kvality života NA vysvetľovala 
13.2% (P<0.001) variancie u mužov a 9.3% (P<0.01) u žien. SI vysvetľovala 
najviac 5.5% (P<0.05) variancie v komunikácii u mužov a 7.3% (P<0.05) v 
dimenzii stigma u žien. Znamená to, že osobnostné vlastnosti hrajú dôležitú 
úlohu pri vysvetľovaní kvality života u pacientov s PD. Rodové rozdiely 
poukazujú na odlišné zloženie modelov kvality života u mužov a u žien. 
Je pravdepodobné, že tieto modely sú zložené z odlišných komponentov. 
V Kapitole 4 prezentujeme systematický prehľad, ktorý sa zameriava 
na úlohu intenzity strachu pri oneskorovaní vyhľadania zdravotnej 
starostlivosti pacientom. Do prehľadu sme zahrnuli články zaoberajúce sa 
štatisticky najčastejšími ochoreniami – rakovinou a infarktom myokardu 
– hlavne z dôvodu početnosti uverejnených článkov k tejto téme. 
Vyhľadávanie literartúry sme obmedzili na časový úsek medzi rokmi 
1990 a 2009 a našli sme 161 relevantných článkov. Po použití vybraných 
kritérií sme do štúdie zahrnuli 11 článkov týkajúcich sa rakoviny (rôznych 
druhov) a 4 články týkajúce sa infarktu myokardu. Strach sa v týchto 
štúdiách pohyboval na škále od ‘byť znepokojený’, čo nestačilo na skoré 
kontaktovanie špecialistu, až po ‘paniku’. Pacienti, ktorý boli extrémne 
vystrašení prvými príznakmi ochorenia, boli pripravení konzultovať ich 
s odborným lekárom v rámci niekoľkých hodín. Hlavným výsledkom 
nášho prehľadového článku bolo poukázať na to, ako miera strachu 
ovplyvňuje rozhodovanie pacienta. Tento dôležitý faktor by mal byť 
vzatý do úvahy vtedy, ak je potrebné pomôcť pacientovi pri rozhodovaní, 
či vyhľadať odborníka. Podpora vyhľadania zdravotnej starostlivosti je 
nutná najmä u pacientov pociťujúcich iba slabé znepokojenie príznakmi 
ochorenia. 
Oneskorovanie vyhľadania zdravotnej starostlivosti bolo témou 
Kapitoly 5. V nej nás zaujímala odpoveď na výskumnú otázku, či 
kvalita života pacientov s PD, ktorí oddiaľovali vyhľadanie zdravotnej 
starostlivosti, súvisí s osobnostnými vlasnosťami. Vzhľadom na 
intermitentný výskyt symptómov parkinsonizmu v začiatkoch ochorenia 
a niekedy pozvoľný nástup ochorenia, pacienti, ktorí vyhľadali zdravotnú 
starostlivosť do 1 roka od spozorovania prvých príznakov ochorenia, boli 
označení za ‘skorých’ (non-delayers) a tí, ktorí ju vyhľadali po 1 roku od 
objavenia sa príznakov za ‘neskorých’ (delayers). Tento časový úsek sme 
zisťovali na základe rozhovoru s pacientom – pokiaľ nástup ochorenia 
neprebehol dramaticky, prvé symptómy ochorenia pripisovali stresu. 
‘Skorí’ pacienti skórovali vyššie na škále extroverzie, čo tiež asociovalo s 
lepším skóre vo fyzickom a mentálnom výslednom skóre kvality života. 117
Výsledky nabádajú k vysvetleniu, že sociálne interakcie, ktoré súvisia 
s extrovertným správaním, môžu posilniť pacienta v jeho rozhodnutí 
vyhľadať odbornú starostlivosť. 
Mnohé štúdie potvrdzujú, že anxieta a depresia sú faktormi, 
ktoré súvisia s horším vnímaním kvality života pacientami s rôznymi 
diagnózami. Pretože sme v predchádzajúcich kapitolách potvrdili, že 
osobnostné vlastnosti (prevažne osobnosť typu D a neuroticizmus) 
determinujú kvalitu života, v Kapitole 6 sme skúmali, či osobnosť typu D 
asociuje s mentálnym a fyzickým komponentom kvality života pacientov 
s PD a sklerosis multiplex (SM) aj vtedy, keď k modelu ich kvality života 
pridáme aj premenné anxietu a depresiu. Naše zistenia potvrdzujú, že 
vyššie skóre anxiety a depresie silne súviselo s mierou kvality života u 
oboch ochorení. Napriek tomu, že osobnosť typu D asociovala s oboma 
dimenziami kvality života – fyzickým aj mentálnym výsledným skóre, 
táto asociácia zmizla u oboch dimenzií pri pacientoch so SM a v diemenzii 
mentálneho výsledného skóre u pacientov s PD, keď sme do modelu pridali 
premenné anxietu a depresiu. Z našich výsledkov vyplýva, že osobnosť 
síce ovplyvňuje kvalitu života, avšak nie priamo, ale prostredníctvom 
porúch nálad. 
Kapitola 7 sa zaoberá diskusiou hlavných výsledkov výskumu a ich 
významom pre prax a ďalší výskum. V súlade s našimi výsledkami môžeme 
konštatovať, že pri hodnotení kvality života pacientov s Parkinsonovou 
chorobou majú vysvetľujúcu hodnotu aj osobnostné vlastnosti. Rodový 
aspekt je témou, ktorá sa tiež javí ako dôležitá pri skúmaní psychologických 
odlišností medzi mužmi a ženami s PD. Prítomnosť porúch nálad, depresie 
a anxiety, modiﬁ  kuje vplyv osobnostných vlastností na vnímanie kvality 
života pacientom a zdá sa, že má vážnejší dopad na kvalitu života nielen 
u pacientov s Parkinsonovou chorobou, ale aj na pacientov so sclerosis 
multiplex. Podľa našich výsledkov, pacienti, ktorí vyhľadajú zdravotnú 
starostlivosť skôr (non-delayers) a pacienti oddiaľujúci vyhľadanie 
zdravotnej starostlivosti (delayers) sa odlišujú v miere extroverzie, ktorá 
pozitívne koreluje so sociálnou aktivitou a sociálnou oporou. Preto 
pacienti, ktorí dosahujú vyššie skóre v extroverzii a ktorí majú možnosť 
zdieľať svoje pocity a obavy s inými ľuďmi, vyhľadávajú zdravotnú 
starostlivosť skôr ako pacenti s nízkym skóre v extroverzii.
K limitáciám tohto výskumu patrila pomerne nízka návratnosť 
dotazníkov, ktorá môže ovplyvniť možnosť generalizácie výsledkov 
na celkovú populáciu pacientov s PD. Použitie longitudinálnych dát v 
budúcom výskume nám pomôže lepšie vysvetliť kauzálne vzťahy medzi 
premennými. Budúci výskum v oblasti oddiaľovania vyhľadania odbornej 
starostlivosti by mal obsahovať analýzu nielen kvantitatívnych, ale aj 
kvalitatívnych údajov, ktorá by mala zabezpečiť presnejšiu interpretáciu 
výsledkov. Použitie kvalitatívnych metód nám môže pomôcť objasniť 
významy a kontext meraných premenných. Z nášho výskumu vyplýva, že 118 ZHRNUTIE
pri výbere najefektívnejšej intervencie pri liečení pacientov s PD je nutné, 
aby neurológ zohľadňoval aj osobnosť pacienta a jeho aktuálnu náladu, 
prípadne motiváciu, nielen zlepšovanie alebo zhoršovanie klinických 
príznakov ochorenia.  119
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The Graduate School Kosice Institute for Society and Health (KISH) was 
established in 2004. The Graduate School KISH is hosted by the Faculty of 
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on Chronic Disease. 
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More information regarding the institute can be obtained from 
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